

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in prostate cancer research:... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1173/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1173" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.">
            <meta name="og:description" content="Read the latest article version by Sander Frank, Peter Nelson, Valeri Vasioukhin, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15784">
            <meta name="article-id" content="14499">
            <meta name="dc.title" content="Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects">
            <meta name="dc.description" content="Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes ( ERG , PTEN , and SPOP ) are recurrently mutated in more than 10% of primary tumors. On the other hand, metastatic castration-resistant tumors have more mutations, but, with the exception of the androgen receptor gene ( AR ), no single gene is altered in more than half of tumors. Structural genomic rearrangements are common, including ERG fusions, copy gains involving the MYC locus, and copy losses containing PTEN . Overall, instead of being associated with a single dominant driver event, prostate tumors display various combinations of modifications in oncogenes and tumor suppressors. This review takes a broad look at the recent advances in PCa research, including understanding the genetic alterations that drive the disease and how specific mutations can sensitize tumors to potential therapies. We begin with an overview of the genomic landscape of primary and metastatic PCa, enabled by recent large-scale sequencing efforts. Advances in three-dimensional cell culture techniques and mouse models for PCa are also discussed, and particular emphasis is placed on the benefits of patient-derived xenograft models. We also review research into understanding how ETS fusions (in particular, TMPRSS2-ERG ) and SPOP mutations contribute to tumor initiation. Next, we examine the recent findings on the prevalence of germline DNA repair mutations in about 12% of patients with metastatic disease and their potential benefit from the use of poly(ADP-ribose) polymerase (PARP) inhibitors and immune modulation. Lastly, we discuss the recent increased prevalence of AR-negative tumors (neuroendocrine and double-negative) and the current state of immunotherapy in PCa. AR remains the primary clinical target for PCa therapies; however, it does not act alone, and better understanding of supporting mutations may help guide the development of novel therapeutic strategies.">
            <meta name="dc.subject" content="prostate cancer, sequencing, xenograft, immunotherapy, 3D culture, PARP, BRCA">
            <meta name="dc.creator" content="Frank, Sander">
            <meta name="dc.creator" content="Nelson, Peter">
            <meta name="dc.creator" content="Vasioukhin, Valeri">
            <meta name="dc.date" content="2018/08/02">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14499.1">
            <meta name="dc.source" content="F1000Research 2018 7:1173">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="prostate cancer">
            <meta name="prism.keyword" content="sequencing">
            <meta name="prism.keyword" content="xenograft">
            <meta name="prism.keyword" content="immunotherapy">
            <meta name="prism.keyword" content="3D culture">
            <meta name="prism.keyword" content="PARP">
            <meta name="prism.keyword" content="BRCA">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/08/02">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1173">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14499.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1173">
            <meta name="citation_title" content="Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects">
            <meta name="citation_abstract" content="Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes ( ERG , PTEN , and SPOP ) are recurrently mutated in more than 10% of primary tumors. On the other hand, metastatic castration-resistant tumors have more mutations, but, with the exception of the androgen receptor gene ( AR ), no single gene is altered in more than half of tumors. Structural genomic rearrangements are common, including ERG fusions, copy gains involving the MYC locus, and copy losses containing PTEN . Overall, instead of being associated with a single dominant driver event, prostate tumors display various combinations of modifications in oncogenes and tumor suppressors. This review takes a broad look at the recent advances in PCa research, including understanding the genetic alterations that drive the disease and how specific mutations can sensitize tumors to potential therapies. We begin with an overview of the genomic landscape of primary and metastatic PCa, enabled by recent large-scale sequencing efforts. Advances in three-dimensional cell culture techniques and mouse models for PCa are also discussed, and particular emphasis is placed on the benefits of patient-derived xenograft models. We also review research into understanding how ETS fusions (in particular, TMPRSS2-ERG ) and SPOP mutations contribute to tumor initiation. Next, we examine the recent findings on the prevalence of germline DNA repair mutations in about 12% of patients with metastatic disease and their potential benefit from the use of poly(ADP-ribose) polymerase (PARP) inhibitors and immune modulation. Lastly, we discuss the recent increased prevalence of AR-negative tumors (neuroendocrine and double-negative) and the current state of immunotherapy in PCa. AR remains the primary clinical target for PCa therapies; however, it does not act alone, and better understanding of supporting mutations may help guide the development of novel therapeutic strategies.">
            <meta name="citation_description" content="Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes ( ERG , PTEN , and SPOP ) are recurrently mutated in more than 10% of primary tumors. On the other hand, metastatic castration-resistant tumors have more mutations, but, with the exception of the androgen receptor gene ( AR ), no single gene is altered in more than half of tumors. Structural genomic rearrangements are common, including ERG fusions, copy gains involving the MYC locus, and copy losses containing PTEN . Overall, instead of being associated with a single dominant driver event, prostate tumors display various combinations of modifications in oncogenes and tumor suppressors. This review takes a broad look at the recent advances in PCa research, including understanding the genetic alterations that drive the disease and how specific mutations can sensitize tumors to potential therapies. We begin with an overview of the genomic landscape of primary and metastatic PCa, enabled by recent large-scale sequencing efforts. Advances in three-dimensional cell culture techniques and mouse models for PCa are also discussed, and particular emphasis is placed on the benefits of patient-derived xenograft models. We also review research into understanding how ETS fusions (in particular, TMPRSS2-ERG ) and SPOP mutations contribute to tumor initiation. Next, we examine the recent findings on the prevalence of germline DNA repair mutations in about 12% of patients with metastatic disease and their potential benefit from the use of poly(ADP-ribose) polymerase (PARP) inhibitors and immune modulation. Lastly, we discuss the recent increased prevalence of AR-negative tumors (neuroendocrine and double-negative) and the current state of immunotherapy in PCa. AR remains the primary clinical target for PCa therapies; however, it does not act alone, and better understanding of supporting mutations may help guide the development of novel therapeutic strategies.">
            <meta name="citation_keywords" content="prostate cancer, sequencing, xenograft, immunotherapy, 3D culture, PARP, BRCA">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Sander Frank">
            <meta name="citation_author_institution" content="Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA">
            <meta name="citation_author" content="Peter Nelson">
            <meta name="citation_author_institution" content="Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA">
            <meta name="citation_author_institution" content="Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA">
            <meta name="citation_author_institution" content="Departments of Medicine and Urology, University of Washington, Seattle, WA 98195, USA">
            <meta name="citation_author_institution" content="Department of Pathology, University of Washington, Seattle, WA 98195, USA">
            <meta name="citation_author" content="Valeri Vasioukhin">
            <meta name="citation_author_institution" content="Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA">
            <meta name="citation_author_institution" content="Department of Pathology, University of Washington, Seattle, WA 98195, USA">
            <meta name="citation_publication_date" content="2018/08/02">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1173">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14499.1">
            <meta name="citation_firstpage" content="1173">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1173/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1173.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15784 /> <input type=hidden id=articleId name=articleId value=14499 /> <input type=hidden id=xmlUrl value="/articles/7-1173/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1173-v1.xml"> <input type=hidden id=article_uuid value=607f2be0-e00b-4aaa-b03c-9752bea6e453 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14499.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14499.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1173"
  },
  "headline": "Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and...",
  "datePublished": "2018-08-02T10:01:30",
  "dateModified": "2018-08-02T10:01:30",
  "author": [
    {
      "@type": "Person",
      "name": "Sander Frank"
    },    {
      "@type": "Person",
      "name": "Peter Nelson"
    },    {
      "@type": "Person",
      "name": "Valeri Vasioukhin"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes (ERG, PTEN, and SPOP) are recurrently mutated in more than 10% of primary tumors. On the other hand, metastatic castration-resistant tumors have more mutations, but, with the exception of the androgen receptor gene (AR), no single gene is altered in more than half of tumors. Structural genomic rearrangements are common, including ERG fusions, copy gains involving the MYC locus, and copy losses containing PTEN. Overall, instead of being associated with a single dominant driver event, prostate tumors display various combinations of modifications in oncogenes and tumor suppressors. This review takes a broad look at the recent advances in PCa research, including understanding the genetic alterations that drive the disease and how specific mutations can sensitize tumors to potential therapies. We begin with an overview of the genomic landscape of primary and metastatic PCa, enabled by recent large-scale sequencing efforts. Advances in three-dimensional cell culture techniques and mouse models for PCa are also discussed, and particular emphasis is placed on the benefits of patient-derived xenograft models. We also review research into understanding how ETS fusions (in particular, TMPRSS2-ERG) and SPOP mutations contribute to tumor initiation. Next, we examine the recent findings on the prevalence of germline DNA repair mutations in about 12% of patients with metastatic disease and their potential benefit from the use of poly(ADP-ribose) polymerase (PARP) inhibitors and immune modulation. Lastly, we discuss the recent increased prevalence of AR-negative tumors (neuroendocrine and double-negative) and the current state of immunotherapy in PCa. AR remains the primary clinical target for PCa therapies; however, it does not act alone, and better understanding of supporting mutations may help guide the development of novel therapeutic strategies."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1173.html",
            "name": "Recent advances in prostate cancer research: large-scale genomic analyses..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in prostate cancer research: large-scale genomic analyses... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15784 data-id=14499 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14499.1" data-recommended="" data-doi="10.12688/f1000research.14499.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1173/v1/pdf?article_uuid=607f2be0-e00b-4aaa-b03c-9752bea6e453" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14499-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14499-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14499-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Frank S, Nelson P and Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1173 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14499.1" target=_blank>https://doi.org/10.12688/f1000research.14499.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14499-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14499 id=track-article-signin-14499 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14499?target=/articles/7-1173.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15784 /> <input name=articleId type=hidden value=14499 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:sfrank@fredhutch.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sander Frank</span></a><a href="https://orcid.org/0000-0001-7591-944X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7591-944X</div><sup>1</sup>,&nbsp;</span><span class="">Peter Nelson<sup>1-4</sup>,&nbsp;</span><span class=""><a href="mailto:vvasiouk@fhcrc.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Valeri Vasioukhin</span></a><a href="https://orcid.org/0000-0002-6730-0281" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6730-0281</div><sup>1,4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:sfrank@fredhutch.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Sander Frank</span></a><a href="http://orcid.org/0000-0001-7591-944X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7591-944X</div><sup>1</sup>,&nbsp;</span><span class="">Peter Nelson<sup>1-4</sup>,&nbsp;</span><span class=""><a href="mailto:vvasiouk@fhcrc.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Valeri Vasioukhin</span></a><a href="http://orcid.org/0000-0002-6730-0281" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6730-0281</div><sup>1,4</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 02 Aug 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14499.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA<br/> <sup>2</sup> Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA<br/> <sup>3</sup> Departments of Medicine and Urology, University of Washington, Seattle, WA 98195, USA<br/> <sup>4</sup> Department of Pathology, University of Washington, Seattle, WA 98195, USA<br/> <p> <div class=margin-bottom> Sander Frank <br/> <span>Roles: </span> Conceptualization, Investigation, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Peter Nelson <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Valeri Vasioukhin <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37062-36419></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37064-36418></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes (<i>ERG</i>, <i>PTEN</i>, and <i>SPOP</i>) are recurrently mutated in more than 10% of primary tumors. On the other hand, metastatic castration-resistant tumors have more mutations, but, with the exception of the androgen receptor gene (<i>AR</i>), no single gene is altered in more than half of tumors. Structural genomic rearrangements are common, including <i>ERG </i>fusions, copy gains involving the <i>MYC</i> locus, and copy losses containing <i>PTEN</i>. Overall, instead of being associated with a single dominant driver event, prostate tumors display various combinations of modifications in oncogenes and tumor suppressors. This review takes a broad look at the recent advances in PCa research, including understanding the genetic alterations that drive the disease and how specific mutations can sensitize tumors to potential therapies. We begin with an overview of the genomic landscape of primary and metastatic PCa, enabled by recent large-scale sequencing efforts. Advances in three-dimensional cell culture techniques and mouse models for PCa are also discussed, and particular emphasis is placed on the benefits of patient-derived xenograft models. We also review research into understanding how ETS fusions (in particular, <i>TMPRSS2-ERG</i>) and <i>SPOP</i> mutations contribute to tumor initiation. Next, we examine the recent findings on the prevalence of germline DNA repair mutations in about 12% of patients with metastatic disease and their potential benefit from the use of poly(ADP-ribose) polymerase (PARP) inhibitors and immune modulation. Lastly, we discuss the recent increased prevalence of AR-negative tumors (neuroendocrine and double-negative) and the current state of immunotherapy in PCa. AR remains the primary clinical target for PCa therapies; however, it does not act alone, and better understanding of supporting mutations may help guide the development of novel therapeutic strategies. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> prostate cancer, sequencing, xenograft, immunotherapy, 3D culture, PARP, BRCA </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Sander Frank (<a href="mailto:sfrank@fredhutch.org">sfrank@fredhutch.org</a>) <br> Valeri Vasioukhin (<a href="mailto:vvasiouk@fhcrc.org">vvasiouk@fhcrc.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Sander Frank, Valeri Vasioukhin </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was funded by the National Institutes of Health: P30CA015704, P50CA097186, and R01CA176844. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Frank S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Frank S, Nelson P and Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1173 (<a href="https://doi.org/10.12688/f1000research.14499.1" target=_blank>https://doi.org/10.12688/f1000research.14499.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 02 Aug 2018, <b>7</b>(F1000 Faculty Rev):1173 (<a href="https://doi.org/10.12688/f1000research.14499.1" target=_blank>https://doi.org/10.12688/f1000research.14499.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 02 Aug 2018, <b>7</b>(F1000 Faculty Rev):1173 (<a href="https://doi.org/10.12688/f1000research.14499.1" target=_blank>https://doi.org/10.12688/f1000research.14499.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e245>Introduction</h2><p class="" id=d21098e248>Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in American men and is estimated to account for about 30,000 deaths this year in the USA and at least 10 times as many worldwide<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The disease is curable when locally confined, but treatment options are limited for metastatic disease. First recognized in the 1940s as an effective therapy for metastatic PCa<sup><a href="#ref-3">3</a></sup>, androgen deprivation remains the primary option for patients with advanced disease; however, tumors invariably relapse into incurable metastatic castration-resistant PCa (mCRPC)<sup><a href="#ref-4">4</a></sup>. Further targeting of the androgen receptor (AR) axis with more effective drugs has extended survival by a few months but leads to resistance, including an increase in once-rare neuroendocrine and non-neuroendocrine/AR-negative tumors<sup><a href="#ref-5">5</a></sup>. Owing to recent large-scale sequencing efforts, there is now a better understanding of the genomic landscape of PCa, including characterization of lower-frequency but nonetheless important mutations in <i>SPOP</i> and DNA repair genes (for example, <i>BRCA2</i>).</p><p class="" id=d21098e277>This review covers some of the recent advances in understanding PCa, including identification and targeting of key genetic aberrations (<i>ERG</i>, <i>SPOP</i>, and DNA repair defects), improvements in disease models, the emergence of AR-negative disease, and current immunotherapy strategies. Although AR signaling remains the ultimate driver of most PCa, tumors show an assortment of additional alterations that help promote disease progression and at the same time provide new opportunities for targeting this resilient disease. Although we sought to cover a wide range of topics, many fell beyond the scope of this report. However, several of those important themes can be found in previous reviews, including epigentics<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>, diet<sup><a href="#ref-8">8</a></sup>, tumor metabolism<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>, biomarkers<sup><a href="#ref-11">11</a></sup>, microRNAs<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>, the role of the microenvironment<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>, and racial disparities<sup><a href="#ref-16">16</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e330>Genomic analysis of primary tumors</h2><p class="" id=d21098e333>Analysis of PCa at the genome level began around the turn of the century with a wide range of studies using a combination of techniques, such as comparative genomic hybridization, DNA microarray, and targeted sequencing<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. Whole genome sequencing (WGS) efforts began around 2011, including a project that performed WGS of seven primary tumors (<a href="#f1">Figure 1</a>)<sup><a href="#ref-19">19</a></sup>. Over the next 2 years, whole exome sequencing (WES) efforts expanded to analyze over a hundred primary tumors<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. A major leap came in 2015 with publication of the data from the PCa branch of The Cancer Genome Atlas (TCGA), a landmark study that published molecular characterization (genomic, epigenomic, and proteomic) of 333 primary prostate tumors<sup><a href="#ref-22">22</a></sup>. Another large-scale study (published in 2017) is the Genomic Hallmarks of Prostate Cancer, which includes WGS for 200 primary tumors and WES for an additional 277<sup><a href="#ref-23">23</a></sup>. Two 2018 studies performed WGS on 92 and 93 additional primary tumors, generating more useful data for analysis<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. One issue that can arise when comparing datasets from different studies is a lack of uniform pipeline analysis (that is, data standardization, normalization, and statistical cutoffs). A 2018 report sought to tackle this problem by re-analyzing 1,013 available WES datasets (680 primary and 333 metastatic) using a common analysis pipeline<sup><a href="#ref-26">26</a></sup>. As a direct result of these transformative studies, researchers finally have an encompassing view of the genetic landscape of primary PCa that provides an important point of reference for understanding this complex disease.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure1.gif"><img alt="fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure1.gif"></a><div class=caption><h3>Figure 1. Timeline (not to scale) of key prostate cancer whole genome sequencing and whole exome sequencing studies<sup><a href="#ref-19">19</a>–<a href="#ref-26">26</a>,<a href="#ref-27">27</a>–<a href="#ref-30">30</a></sup>.</h3><p id=d21098e400>One of these studies included 10 hormone treatment-naïve metastatic tumors (metastatic prostate cancer)<sup><a href="#ref-24">24</a></sup>. *A total of 293 primary tumors were analyzed in this study, but 200 were included in a previous study and not included here<sup><a href="#ref-23">23</a></sup>. The study by Armenia <i>et al</i>.<sup><a href="#ref-26">26</a></sup> is a uniform re-analysis of previous whole exome sequencing studies, including many of those listed here. mCRPC, metastatic castration-resistant prostate cancer; mPC, metastatic prostate cancer; TCGA, The Cancer Genome Atlas; WES, whole exome sequencing; WGS, whole genome sequencing.</p></div></div><p class="" id=d21098e422>At a broad glance, prostate tumors have, on average, fewer mutations (0.7 per Mb) than other common cancers, such as breast (1.2 per Mb), bladder (7.1 per Mb), colorectal (3.1 per Mb), and melanoma (12.1 per Mb)<sup><a href="#ref-31">31</a></sup>. Despite having relatively few point mutations, PCa is characterized by a high rate of genomic instability and chromosomal rearrangments<sup><a href="#ref-32">32</a></sup>. The most frequent genomic aberration in primary tumors is a chromosomal rearrangement fusing strong AR-regulated promoters with ETS family genes (62%), resulting in their prominent overexpression (<a href="#T1">Table 1</a>)<sup><a href="#ref-22">22</a></sup>. Although multiple ETS fusions have been identified, the most common is <i>TMPRSS2-ERG</i>, which arises from an approximately 3 Mb deletion on chromosome 21 that brings the androgen-regulated <i>TMPRSS2</i> promoter upstream of <i>ERG</i><sup><a href="#ref-22">22</a>,<a href="#ref-33">33</a></sup>. In addition, about 3% of primary tumors show mutation/deletion of <i>ERF</i>, an ETS repressive cofactor, providing another mechanism for increasing ETS activity without their overexpression<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. Other common genomic alterations in primary tumors include loss (usually by deletion) of <i>PTEN</i> (17%), point mutations in <i>SPOP</i> (11%), mutation or deletion of <i>TP53</i> (8%), and amplification of <i>MYC</i> (7%) (<a href="#T1">Table 1</a>)<sup><a href="#ref-22">22</a></sup>. Many of the findings from these sequencing efforts confirmed previously known alterations (for example, <i>ERG</i>, <i>MYC</i>, and <i>PTEN</i>)<sup><a href="#ref-38">38</a></sup>, but they also revealed some less-frequent, novel PCa mutations (for example, <i>SPOP</i>, <i>IDH1</i>, <i>MED12</i>, and <i>FOXA1</i>)<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. The majority of these studies also included mRNA expression or DNA methylation data or both. Information concerning changes in gene expression, mutations, deletions, and amplifications in human PCa can be readily queried via the cBioPortal web tool (<a target=xrefwindow href="http://www.cbioportal.org" id=d21098e519>www.cbioportal.org</a>)<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Common genomic aberrations in primary prostate cancer.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21098e541 class=n-a></a><thead><a name=d21098e543 class=n-a></a><tr><a name=d21098e545 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e547 class=n-a></a>Gene</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e550 class=n-a></a>Primary<br class=br>tumors altered,<br class=br>percentage</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e557 class=n-a></a>Type of<br class=br>mutation</th></tr></thead><tbody><a name=d21098e564 class=n-a></a><tr><a name=d21098e566 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e568 class=n-a></a>ETS family<sup><a href="#fn1">a</a></sup> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e575 class=n-a></a>62</td><td colspan=1 rowspan=1 valign=top><a name=d21098e578 class=n-a></a>Fusion/Amp</td></tr><tr><a name=d21098e582 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e584 class=n-a></a> <i>ERG</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e590 class=n-a></a>46</td><td colspan=1 rowspan=1 valign=top><a name=d21098e593 class=n-a></a>Fusion</td></tr><tr><a name=d21098e597 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e599 class=n-a></a> <i>PTEN</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e605 class=n-a></a>17</td><td colspan=1 rowspan=1 valign=top><a name=d21098e608 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e612 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e614 class=n-a></a> <i>SPOP</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e620 class=n-a></a>11</td><td colspan=1 rowspan=1 valign=top><a name=d21098e623 class=n-a></a>Mut</td></tr><tr><a name=d21098e627 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e629 class=n-a></a> <i>TP53</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e635 class=n-a></a>8</td><td colspan=1 rowspan=1 valign=top><a name=d21098e638 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e643 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e645 class=n-a></a> <i>MYC</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e651 class=n-a></a>7</td><td colspan=1 rowspan=1 valign=top><a name=d21098e654 class=n-a></a>Amp</td></tr><tr><a name=d21098e658 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e660 class=n-a></a> <i>AR</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e666 class=n-a></a>1</td><td colspan=1 rowspan=1 valign=top><a name=d21098e669 class=n-a></a>Amp</td></tr><tr><a name=d21098e673 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e675 class=n-a></a> <i>RB1</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e681 class=n-a></a>1</td><td colspan=1 rowspan=1 valign=top><a name=d21098e684 class=n-a></a>Homdel/Mut</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21098e692 class=n-a></a><p id=fn1> A selection of common alterations in primary prostate tumors. cBioPortal<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup> was used to query the TCGA (The Cancer Genome Atlas) data set, which contains 333 primary tumor samples<sup><a href="#ref-22">22</a></sup>. Data were queried specifically for the type of alterations listed in the third column. Amp, genomic amplification; Homdel, homozygous deletion; Mut, nonsynonymous mutation. <sup>a</sup><i>ERG</i>, <i>ETV1/4/5</i>, <i>FLI1</i>.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e723>Genomic analysis of metastatic tumors</h2><p class="" id=d21098e726>Understanding the genomic landscape of primary tumors has many benefits (for example, understanding tumor origin, aiding prognosis, and revealing therapy options), but there is also a more practical need to understand the lethal form of disease, mCRPC. Androgen deprivation and AR signaling inhibitors (ARSis) (for example, abiraterone and enzalutamide) are initially quite effective, but tumors eventually develop resistance via various mechanisms, including (but not limited to) intra-tumoral androgen synthesis, AR amplification, AR ligand-binding domain mutations, or expression of constitutively active AR splice variants<sup><a href="#ref-4">4</a>,<a href="#ref-39">39</a></sup>. Sequencing efforts with metastatic tumors (<a href="#f1">Figure 1</a>) identified enrichment of some mutations seen in primary disease, including amplification/mutation of <i>AR</i> (61%), amplification of <i>MYC</i> (20%), and deletion/mutation of <i>TP53</i> (47%) and <i>PTEN</i> (41%) (<a href="#T2">Table 2</a>)<sup><a href="#ref-27">27</a>–<a href="#ref-30">30</a></sup>. mCRPC tumors have about five times as many mutations as primary tumors (2.3~4.4 versus 0.7~1.0 per Mb)<sup><a href="#ref-24">24</a>,<a href="#ref-28">28</a>,<a href="#ref-31">31</a></sup> and include several new mutations, a selection of which is summarized in <a href="#T2">Table 2</a>. One key advantage of having sequencing data from hundreds of tumors is the ability to use bioinformatics to recognize and cluster low-frequency, recurrent mutations across multiple genes in a single pathway. At the pathway level, mCRPC tumors have frequent alterations in AR signaling (71%), PI3K/PTEN (49%), WNT (18%), cell cycle (21%), and DNA repair (13%)<sup><a href="#ref-28">28</a></sup>. Furthermore, about 21% of mCRPC tumors have amplified <i>HEY1</i>, which is an important target of the NOTCH pathway (<a href="#T2">Table 2</a>)<sup><a href="#ref-38">38</a></sup>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Common genomic aberrations in metastatic prostate cancer.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21098e801 class=n-a></a><thead><a name=d21098e803 class=n-a></a><tr><a name=d21098e805 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e807 class=n-a></a>Gene</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e810 class=n-a></a>mCRPC<br class=br>altered,<br class=br>percentage</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e817 class=n-a></a>Chromosome</th><th align=left colspan=1 rowspan=1 valign=top><a name=d21098e820 class=n-a></a>Type of<br class=br>mutation</th></tr></thead><tbody><a name=d21098e827 class=n-a></a><tr><a name=d21098e829 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e831 class=n-a></a> <i>AR</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e837 class=n-a></a>61</td><td colspan=1 rowspan=1 valign=top><a name=d21098e840 class=n-a></a>Xq</td><td colspan=1 rowspan=1 valign=top><a name=d21098e843 class=n-a></a>Amp/Mut</td></tr><tr><a name=d21098e847 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e849 class=n-a></a>ETS family<sup><a href="#fn2">a</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d21098e855 class=n-a></a>49</td><td colspan=1 rowspan=1 valign=top><a name=d21098e858 class=n-a></a>-</td><td colspan=1 rowspan=1 valign=top><a name=d21098e861 class=n-a></a>Fusion/Amp</td></tr><tr><a name=d21098e865 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e867 class=n-a></a> <i>ERG</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e873 class=n-a></a>35</td><td colspan=1 rowspan=1 valign=top><a name=d21098e876 class=n-a></a>21q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e879 class=n-a></a>Fusion</td></tr><tr><a name=d21098e883 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e885 class=n-a></a> <i>TP53</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e891 class=n-a></a>47</td><td colspan=1 rowspan=1 valign=top><a name=d21098e894 class=n-a></a>17p</td><td colspan=1 rowspan=1 valign=top><a name=d21098e897 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e901 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e903 class=n-a></a> <i>PTEN</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e909 class=n-a></a>43</td><td colspan=1 rowspan=1 valign=top><a name=d21098e912 class=n-a></a>10q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e915 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e920 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e922 class=n-a></a> <i>HEY1</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e928 class=n-a></a>21</td><td colspan=1 rowspan=1 valign=top><a name=d21098e931 class=n-a></a>8q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e934 class=n-a></a>Amp</td></tr><tr><a name=d21098e938 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e940 class=n-a></a> <i>E2F5</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e946 class=n-a></a>21</td><td colspan=1 rowspan=1 valign=top><a name=d21098e949 class=n-a></a>8q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e952 class=n-a></a>Amp</td></tr><tr><a name=d21098e956 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e958 class=n-a></a> <i>MYC</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e964 class=n-a></a>20</td><td colspan=1 rowspan=1 valign=top><a name=d21098e967 class=n-a></a>8q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e970 class=n-a></a>Amp</td></tr><tr><a name=d21098e974 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e976 class=n-a></a> <i>RB1</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e982 class=n-a></a>17</td><td colspan=1 rowspan=1 valign=top><a name=d21098e985 class=n-a></a>13q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e988 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e992 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e994 class=n-a></a> <i>FOXA1</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1000 class=n-a></a>14</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1003 class=n-a></a>14q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1006 class=n-a></a>Amp/Mut</td></tr><tr><a name=d21098e1010 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1012 class=n-a></a> <i>CHD1</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1018 class=n-a></a>11</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1021 class=n-a></a>5q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1024 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e1029 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1031 class=n-a></a> <i>FOXO1</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1037 class=n-a></a>11</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1040 class=n-a></a>13q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1043 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e1047 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1049 class=n-a></a> <i>BRCA2</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1055 class=n-a></a>11</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1058 class=n-a></a>13q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1061 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e1065 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1067 class=n-a></a> <i>MED12</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1073 class=n-a></a>9</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1076 class=n-a></a>Xq</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1079 class=n-a></a>Amp/Mut</td></tr><tr><a name=d21098e1083 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1085 class=n-a></a> <i>SPOP</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1091 class=n-a></a>8</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1094 class=n-a></a>17q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1097 class=n-a></a>Mut</td></tr><tr><a name=d21098e1101 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1103 class=n-a></a> <i>ATM</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1109 class=n-a></a>8</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1112 class=n-a></a>11q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1115 class=n-a></a>Homdel/Mut</td></tr><tr><a name=d21098e1119 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1121 class=n-a></a> <i>PIK3CA</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1127 class=n-a></a>8</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1130 class=n-a></a>3q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1133 class=n-a></a>Amp/Mut</td></tr><tr><a name=d21098e1138 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e1140 class=n-a></a> <i>CDK12</i> </td><td colspan=1 rowspan=1 valign=top><a name=d21098e1146 class=n-a></a>5</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1149 class=n-a></a>17q</td><td colspan=1 rowspan=1 valign=top><a name=d21098e1152 class=n-a></a>Mut</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21098e1160 class=n-a></a><p id=fn2> A selection of common alterations in metastatic castration-resistant prostate cancer (mCRPC). cBioPortal<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup> was used to query three mCRPC data sets containing 347 tumors from 263 patients<sup><a href="#ref-27">27</a>–<a href="#ref-29">29</a></sup>. The second column shows the percentage of patients with a tumor carrying the alteration. Data were queried specifically for the type of alterations listed in the third column. Amp, genomic amplification; Homdel, homozygous deletion; Mut, nonsynonymous mutation. <sup>a</sup><i>ERG</i>, <i>ETV1/4/5</i>, <i>FLI1</i>.</p></div></div></div><p class="" id=d21098e1193>Other recent advances in analyzing mCRPC include circulating tumor cell (CTC) isolation and single-cell sequencing<sup><a href="#ref-40">40</a>–<a href="#ref-42">42</a></sup>. In a 2015 report, the authors used single-cell RNA sequencing on 76 CTCs from 12 patients with mCRPC and found enrichment in expression of stem cell genes, non-canonical WNT signaling, and a range of <i>AR</i> splice variants, sometimes even within the same cell<sup><a href="#ref-41">41</a></sup>. In patients with multiple metastases, tumors usually share common driver mutations and appear to either be clonal or show convergent selection for therapy resistance<sup><a href="#ref-29">29</a>,<a href="#ref-43">43</a></sup>. Moreover, one report analyzed sequencing of multiple metastases within patients and observed that many seeded from an earlier metastasis<sup><a href="#ref-43">43</a></sup>. The authors also found that metastases within a patient are likely to share tumor suppressor loss-of-function mutations (for example, <i>PTEN</i> and <i>TP53</i>) but often show unique AR pathway alterations<sup><a href="#ref-43">43</a></sup>. Although targeting AR by androgen deprivation and ARSi leads to temporary success, there is a clear need to consider other targets, and these recent genomic studies have helped provide some candidates.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e1235>Three-dimensional culture models</h2><p class="" id=d21098e1238>PCa research has advanced with a relatively small collection of commonly used cell lines (and their derivatives), the vast majority of which were isolated from metastatic tumors (for example, LNCaP, VCaP, PC3, and DU145)<sup><a href="#ref-44">44</a></sup>. The overwhelming majority of cells in human PCas most resemble luminal epithelial cells and have some basal marker expression<sup><a href="#ref-38">38</a></sup>. Unlike the mouse prostate, normal human luminal epithelial cells rarely proliferate and most come from bipotent progenitors in the basal layer<sup><a href="#ref-45">45</a></sup>. It is difficult to establish and maintain human luminal epithelial cells in culture; however, luminal-like cells can be differentiated from basal/intermediate cells, which can be maintained in culture<sup><a href="#ref-46">46</a>–<a href="#ref-49">49</a></sup>. Extracellular matrix conditions can have a significant impact on cell survival and growth. For example, plating PCa cells on laminin can activate integrin α6 (also known as CD49f), which aids invasion and survival<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. It is not clear why primary tumors and normal luminal cells take so poorly to tissue culture conditions. It is likely that something within the <i>in vivo</i> microenvironment has not been properly replicated in culture (paracrine factors, cell–cell interactions, and so on). As a way to better mimic the <i>in vivo</i> microenvironment, research has expanded into three-dimensional (3D) culture systems.</p><p class="" id=d21098e1274>Prostate cell culture in 3D (that is, spheroids, prostaspheres, and organoids) has aided research by providing more physiologically relevant conditions and allowing more complex cultures<sup><a href="#ref-52">52</a>–<a href="#ref-54">54</a></sup>. Organoids can be derived from tumors or normal prostate cells, which can recapitulate basal, intermediate, and luminal cells as well as tumor initiation events such as prostatic intra-epithelial neoplasia (PIN)<sup><a href="#ref-55">55</a>–<a href="#ref-59">59</a></sup>. 3D culture can also incorporate different cell types, such as combining epithelial cells plus stroma or cancer cells plus osteoblasts<sup><a href="#ref-60">60</a>–<a href="#ref-62">62</a></sup>. Growing primary human tumors in 3D remains a difficult task, but metastatic tumors have been cultured with some success<sup><a href="#ref-52">52</a>,<a href="#ref-58">58</a>,<a href="#ref-63">63</a></sup>. Innovative studies using organoid cultures have also improved our understanding of prostate tumor initiation and cell of origin<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. A 2016 report provides a protocol for growing prostate organoids using a fairly complex serum-free medium with a variety of growth factors and inhibitors<sup><a href="#ref-52">52</a>,<a href="#ref-58">58</a>,<a href="#ref-66">66</a></sup>. Interestingly, many cell lines behave differently in 2D versus 3D culture; for example, LNCaP cells have higher docetaxel resistance in 3D<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup>. Though technically challenging, these new culture methods allow better modeling of normal and tumor epithelial structure. However, better understanding of prostate cell biology is needed so we can more efficiently culture prostate tissues, especially primary tumors.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e1336>Genetically modified mouse models</h2><p class="" id=d21098e1339>Mouse models have been extremely useful for studying disease initiation and progression <i>in vivo</i> and can broadly be separated into two categories: genetically engineered mouse (GEM) models and xenograft models (<a href="#f2">Figure 2</a>)<sup><a href="#ref-69">69</a></sup>. GEM models rely on engineering the mouse genome to knockout or express specific genes, which can be done globally (classic) or in specific tissues (conditional) via tissue-specific promoter-driven expression of Cre recombinase paired with floxed (flanked-loxP) target alleles (<a href="#f2">Figure 2A</a>). For prostate-specific expression, the most commonly used promoter is the rat Probasin promoter (Pb), the Large Pb (LPB), or the related ARR<sub>2</sub>Pb, which contains Pb plus enhancer elements for higher expression<sup><a href="#ref-72">72</a>,<a href="#ref-88">88</a></sup>. Another common driver for conditional models is a tamoxifen-inducible knock-in Cre (CreERT2) at the <i>Nkx3.1</i> locus, which is more specific for prostate luminal cells but carries the caveat of losing one functional copy of the gene<sup><a href="#ref-74">74</a></sup>. With CreERT2 models, Cre is still made only in the promoter-specified tissues but must be activated by the addition of tamoxifen (which causes nuclear localization) and thus grants far greater temporal control of recombination. Other valuable CreERT2 drivers include the basal keratins 5 and 14 (K5 and K14) and the luminal keratin 8 (K8)<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a>,<a href="#ref-89">89</a>,<a href="#ref-90">90</a></sup>. These keratin promoters provide basal/luminal specificity in the prostate but are also expressed in many other epithelial tissues. These models have been especially useful for lineage-tracing experiments, which use a brief pulse of tamoxifen to tag epithelial cells with fluorescent proteins and follow them as they divide and differentiate over time<sup><a href="#ref-76">76</a></sup>.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure2.gif"><img alt="fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure2.gif"></a><div class=caption><h3>Figure 2. Overview of mouse models of prostate cancer.</h3><p id=d21098e1400>(<b>A</b>) Genetically engineered mouse models. Classic models use the prostate-specific Probasin (Pb) or ARR<sub>2</sub>Pb promoter to drive expression of oncogenes, including <i>MYC</i><sup><a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup> and N-terminally truncated <i>ERG</i><sup><a href="#ref-71">71</a></sup>. In the classic TRAMP model, Pb is used to drive expression of large and small SV40 T-antigen (Tag)<sup><a href="#ref-72">72</a></sup>. The LADY models use the Large Pb (LPB) promoter to drive large T-antigen only<sup><a href="#ref-73">73</a></sup>. Conditional models use prostate-specific Cre recombinase expression with loxP tagged alleles. Cre is most frequently driven by Probasin (Pb-Cre4 line) or a knock-in tamoxifen-inducible Cre at the <i>Nkx3.1</i> locus (Nkx3-1<sup>CreERT2</sup> line)<sup><a href="#ref-74">74</a></sup>. Basal (K5) or luminal (K8) keratin promoters can been used to drive layer-specific expression in the prostate but also are expressed in other epithelial tissues<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. Flanked loxP (floxed) sites can be used to induce loss-of-function deletions in endogenous tumor suppressor genes, including <i>Smad4</i><sup><a href="#ref-77">77</a></sup>, <i>Trp53</i><sup><a href="#ref-78">78</a></sup>, <i>Pten</i><sup><a href="#ref-79">79</a></sup>, and <i>Rb1</i><sup><a href="#ref-80">80</a></sup>. Lox-STOP-lox (LSL) alleles use Cre to remove an upstream STOP codon and allow expression of an oncogene. For constitutive expression, genes can be knocked-in at the ubiquitously expressed <i>Rosa26</i> locus (for example, <i>ERG</i><sup><a href="#ref-81">81</a></sup>, <i>SPOP</i><sup>[<i>F133V</i>]</sup><sup><a href="#ref-82">82</a></sup>, Notch1 intra-cellular domain [NICD1]<sup><a href="#ref-83">83</a></sup>). Alternately, mutant genes can be knocked-in at the endogenous locus to maintain normal transcriptional regulation (for example, <i>Kras</i><sup>[<i>G12D</i>]</sup><sup><a href="#ref-84">84</a></sup> and <i>Braf</i><sup>[<i>V600E</i>]</sup><sup><a href="#ref-85">85</a></sup>). There is also a model where loxP sites are used to delete the intergenic space between <i>Tmprss2</i> and <i>Erg</i>, thereby mimicking the fusion observed in tumors<sup><a href="#ref-86">86</a>,<a href="#ref-87">87</a></sup>. Color coding: white = promoter, green = Cre or lox, blue = endogenous tumor suppressor, red = oncogene, brown = other endogenous gene. (<b>B</b>) Xenograft models. Cells can be injected into immunocompromised mice via multiple methods: (i) subcutaneous, (ii) prostate (orthotopic for primary tumors), (iii) intra-tibial (orthotopic for bone metastatic tumors), (iv) renal capsule, and (v) tail vein.</p></div></div><p class="" id=d21098e1544>There are GEM models matching many of the common alterations observed in human prostate tumors, including <i>MYC</i> overexpression<sup><a href="#ref-70">70</a>,<a href="#ref-91">91</a></sup>, <i>Pten</i> loss<sup><a href="#ref-79">79</a>,<a href="#ref-92">92</a></sup>, <i>ERG</i> overexpression<sup><a href="#ref-81">81</a>,<a href="#ref-86">86</a>,<a href="#ref-93">93</a></sup>, and <i>SPOP</i> mutation<sup><a href="#ref-82">82</a></sup> (<a href="#f2">Figure 2A</a>). The first-generation mouse models of PCa (TRAMP and LADY) used Pb-driven SV40 T-antigen (Tag), which promotes massive proliferation and creates tumors displaying partial neuroendocrine differentiation<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. These models have regained some popularity recently, as neuroendocrine tumors are becoming more common in human PCa. Some prostate GEM models give rise to metastasis, but only one, the LPB-Tag/Pb-Hepsin model expressing SV40 and cell-surface protease Hepsin, reliably metastasizes to bone (up to 40% by 23 weeks of age), the most frequent site in human patients<sup><a href="#ref-77">77</a>,<a href="#ref-94">94</a>–<a href="#ref-96">96</a></sup>. Other GEM models used for PCa are included in <a href="#f2">Figure 2A</a> and have been previously reviewed<sup><a href="#ref-97">97</a>–<a href="#ref-99">99</a></sup>. In summary, recent advancements in GEM models enable the study of autochthonously developing PCa in immune-competent animals, but they lack the complexity of human genetics and human prostate biology and rely on contrived genetic manipulations. To study human tumors <i>in vivo</i>, experiments rely on xenograft models.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e1626>Xenograft mouse models</h2><p class="" id=d21098e1629>With xenograft models, human samples (tissue or cell line) are implanted into immune-compromised mice. Samples can be engrafted via a variety of routes, and the most common is subcutaneous, orthotopic, renal capsule, or tail vein (<a href="#f2">Figure 2B</a>)<sup><a href="#ref-100">100</a></sup>. Subcutaneous grafts allow easy injection and monitoring of tumor growth, while orthotopic injections benefit from a proper microenvironment at the cost of more difficult injection and monitoring. Orthotopic injections can be made into the prostate (for primary tumors) or the metastatic site, including intra-tibial injections for studying bone metastasis (<a href="#f2">Figure 2B</a>)<sup><a href="#ref-101">101</a></sup>. Renal capsule implant is somewhat of a compromise between subcutaneous and orthotopic: a moderately difficult grafting site that is favorable for prostate tissue growth<sup><a href="#ref-100">100</a></sup>. Lastly, tail vein injections require single-cell suspensions and enable investigation of extravasation and metastasis establishment<sup><a href="#ref-102">102</a></sup>.</p><p class="" id=d21098e1655>Patient-derived xenografts (PDXs) specifically use human tumor samples for engrafting into mice<sup><a href="#ref-63">63</a>,<a href="#ref-103">103</a></sup>. These models allow propagation of tumors (metastatic and primary) that do not grow well in culture; however, PDX tumors require continual passage in mice, which adds considerable cost<sup><a href="#ref-63">63</a></sup>. The PCa field has had successful PDX models since the late 1990s, but the procedure is laborious and most reports describe only few (&lt;10) established lines<sup><a href="#ref-104">104</a></sup>. The number of available PDX lines was greatly expanded with the LuCaP series, which was first reported in 1996 with two lines and currently consists of 21 ongoing founder lines from a variety of samples, including four primary tumors and 17 metastases<sup><a href="#ref-63">63</a>,<a href="#ref-105">105</a></sup>. Moreover, 10 of the lines have undergone castration in mice to yield castration-resistant variants<sup><a href="#ref-63">63</a></sup>. The overall initial take rate of the LuCaP PDX lines was about 10% and, once established, most lines have a take rate of about 60% to 80% and take 4 to 16 weeks to reach maximum size (~1,000 mg). Genomic analysis of the LuCaP tumors revealed that most maintained their genomic profile from the original patient sample<sup><a href="#ref-63">63</a></sup>. The lines contain a variety of hallmark mutations, including <i>AR</i> amplification (eight lines), <i>PTEN</i> loss (eight heterozygous and four homozygous), <i>RB1</i> loss (10 heterozygous and six homozygous), <i>TMPRSS2-ERG</i> fusion (10), <i>BRCA2</i> homozygous loss (one), and neuroendocrine subtype (four)<sup><a href="#ref-63">63</a></sup>. PDX models continue to evolve and enable researchers to test a variety of therapeutic strategies against a range of genomic tumor backgrounds and to better understand tumor resistance mechanisms.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e1712>Progress in understanding the role of ETS factors</h2><p class="" id=d21098e1715>One of the unique genomic alterations in PCa is the recurrent fusions involving strong AR-regulated promotors to ETS family transcription factors (most frequently, <i>ERG</i>)<sup><a href="#ref-27">27</a>,<a href="#ref-33">33</a></sup>. In normal prostate tissue, <i>ERG</i> is expressed at very low levels, but it is overexpressed in PIN and adenocarcinoma<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup>. The most frequent fusion (caused by a 3 Mb deletion) joins the <i>TMPRSS2</i> promoter upstream of <i>ERG</i> (<a href="#f3">Figure 3A</a>), although other fusions have been observed with alternate promoters (for example, <i>FOXA1</i>, <i>FOXP1</i>, <i>EST14</i>, and <i>HERVK17</i>) and ETS family members (<i>ETV1</i>, <i>ETV4</i>, <i>ETV5</i>, and <i>FLI1</i>)<sup><a href="#ref-22">22</a>,<a href="#ref-27">27</a>,<a href="#ref-108">108</a></sup>. Likewise, loss of the ETS family transcriptional repressor <i>ERF</i> (though much less common) can also stimulate oncogenic ETS activity<sup><a href="#ref-36">36</a></sup>. ETS fusions are observed at similar frequencies in primary and mCRPC tumors<sup><a href="#ref-28">28</a></sup>, tend to co-occur with <i>PTEN</i> loss<sup><a href="#ref-22">22</a></sup>, and are mutually exclusive with each other and <i>SPOP</i> mutations<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a>,<a href="#ref-82">82</a></sup>. Though ETS factors (especially <i>ERG</i>) are frequently altered in PCa, research is ongoing to understand exactly what role they play in disease initiation or progression or both.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure3.gif"><img alt="fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure3.gif"></a><div class=caption><h3>Figure 3. Overview of ERG fusion and targeted therapies.</h3><p id=d21098e1829> (<b>A</b>) The most common ETS fusion arises from a 3 Mb deletion on chromosome 21, which brings the androgen receptor (AR)-regulated <i>TMPRSS2</i> promoter (light red) upstream of the <i>ERG</i> gene (dark blue), usually clipping the first three to five exons of <i>ERG</i> in the process. (<b>B</b>) A schematic showing mechanisms of anti-ERG therapies. Inhibitory peptides block ERG binding to DNA and cause protein destabilization<sup><a href="#ref-110">110</a></sup>. Verteporfin blocks YAP1, a downstream target of ERG<sup><a href="#ref-93">93</a></sup>. YK-4-279 blocks ERG interaction with RNA helicase A (RHA), thereby disrupting transcription of targets<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup>. Lastly, trabectedin binds minor grooves in ERG binding sites and disrupts its binding to target promoters<sup><a href="#ref-113">113</a></sup>.</p></div></div><p class="" id=d21098e1871>GEM models have been used as one way to investigate the role of <i>ERG</i> in PCa development. A 2007 report used mice with Pb-driven overexpression of <i>ETV1</i> (Pb-<i>ETV1</i>) and observed PIN<sup><a href="#ref-109">109</a></sup>. Other researchers found that high <i>ERG</i> overexpression leads to PIN lesions and disorganization of the basal cell layer in adult animals, that more lesions form as the mice age, and that there is a partially penetrant tumor phenotype in old (16- to 24-month-old) mice<sup><a href="#ref-71">71</a>,<a href="#ref-93">93</a></sup>. The expression level of <i>ERG</i> is critical, as mouse strains with lower levels of <i>ERG</i> overexpression do not develop tumors<sup><a href="#ref-71">71</a></sup>. One study found that expression of <i>ERG</i> in heterozygous <i>Pten</i> mice causes high-grade PIN at 2 months and invasive carcinoma by 6 months and that heterozygous <i>Pten</i> mice without <i>ERG</i> developed PIN at 8 months and no adenocarcinoma<sup><a href="#ref-114">114</a></sup>. Similarly, compared with <i>Pten</i> control mice, mice with conditional prostate-specific deletion of <i>Pten</i> and overexpression of <i>ERG</i> display statistically significant acceleration of prostate tumor development<sup><a href="#ref-81">81</a></sup>. Thus, <i>ERG</i> overexpression is a weak driver of tumor development in mice, but it can accelerate tumor development in the context of <i>Pten</i> downregulation<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a></sup>.</p><p class="" id=d21098e1952>Another avenue of research involves defining specific targets and mechanisms of ETS factors in prostate tumorigenesis. There is evidence that <i>ERG</i> can act in part by modulating AR transcriptional activity, although the mechanism may depend on <i>PTEN</i> status<sup><a href="#ref-81">81</a>,<a href="#ref-116">116</a>,<a href="#ref-117">117</a></sup>. <i>ERG</i> has also been reported to positively regulate <i>MYC</i><sup><a href="#ref-115">115</a>,<a href="#ref-118">118</a></sup> and <i>NOTCH</i><sup><a href="#ref-119">119</a></sup>, both of which are key for prostate differentiation and tumor development, suggesting that <i>ERG</i> may have a role in disrupting terminal differentiation<sup><a href="#ref-38">38</a>,<a href="#ref-120">120</a>,<a href="#ref-121">121</a></sup>. In addition, <i>ERG</i> overexpression leads to increased endoplasmic reticulum stress in LNCaP cells and the prostates of aged Pb-<i>ERG</i> mice<sup><a href="#ref-122">122</a></sup>. Transcriptional analysis of <i>ERG</i> overexpression in mice revealed upregulation of a <i>YAP1</i> gene signature, suggesting an interaction with the Hippo tumor suppressor pathway<sup><a href="#ref-93">93</a></sup>. Mechanistically, it was found that <i>YAP1</i> and <i>TAZ</i>, the transcriptional effectors negatively regulated by the Hippo pathway, are normally expressed at very low levels in human prostate luminal cells but they can be transcriptionally re-activated by overexpressed <i>ERG</i> and <i>ETV1</i><sup><a href="#ref-93">93</a>,<a href="#ref-123">123</a>–<a href="#ref-125">125</a></sup>. Knockdown and constitutive activation experiments established <i>YAP1</i> as a key functional target of <i>ERG</i> in prostate cells <i>in vitro</i><sup><a href="#ref-93">93</a>,<a href="#ref-123">123</a>–<a href="#ref-125">125</a></sup>. Moreover, expression of constitutively active YAP1 in the mouse prostate is sufficient to drive PIN and partially penetrant tumor formation in older mice, similar to the effects of <i>ERG</i> overexpression<sup><a href="#ref-93">93</a></sup>. Knockdown of <i>Erf</i> in mouse prostate organoids upregulates an ERG signature and, when combined with <i>Pten</i> knockout, leads to tumor formation upon subcutaneous engraftment<sup><a href="#ref-36">36</a></sup>. With these recent studies, some of the functions of <i>ERG</i> in PCa are becoming clearer, although much remains to be discovered. Overall, ETS factors appear to be important drivers in PCa development, but their full effects may be seen only in the context of other alterations (for example, <i>AR</i>, <i>PTEN</i>, <i>MYC</i>, and <i>NOTCH</i>), and cross-talk between these pathways is still being investigated.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e2101>Targeting of ETS factors</h2><p class="" id=d21098e2104>Direct targeting of transcription factors is notoriously difficult but not impossible<sup><a href="#ref-126">126</a></sup>. One route is to target a downstream effector of ERG that is more amenable to inhibitors, such as YAP, which can be inhibited by verteporfin (<a href="#f3">Figure 3B</a>). Verteporfin treatment decreases VCaP (ERG<sup>+</sup>) xenograft tumor growth in mice<sup><a href="#ref-93">93</a></sup>. In efforts to target ERG directly, phage-display library screens have been used to identify 12 ERG inhibitory peptides<sup><a href="#ref-110">110</a></sup>. Two of the peptides were modified (to improve cell permeability and localize to the nucleus) and tested <i>in vitro</i> and <i>in vivo</i>. The peptides disrupted DNA binding, destabilized ERG (<a href="#f3">Figure 3B</a>), decreased VCaP and PC3-ERG invasion, and reduced VCaP xenograft growth<sup><a href="#ref-110">110</a></sup>.</p><p class="" id=d21098e2139>Important lessons may be learned from another cancer type with recurrent ETS fusions, Ewing’s sarcoma, in which more than 90% of tumors are driven by a rearrangement fusing the <i>EWSR1</i> gene to <i>FLI1</i>, a paralog of <i>ERG</i><sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>. ETS fusions do occur in some other cancers, but it is not a frequent event<sup><a href="#ref-129">129</a></sup>. YK-4-279, a FLI1 inhibitor initially developed for Ewing’s sarcoma, was reported to shrink PCa tumors in ERG<sup>+</sup> mouse xenograft models (<a href="#f3">Figure 3B</a>)<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup>. Another potential candidate from the Ewing’s sarcoma field is trabectedin (and its second-generation analogue lurbinectedin), which works in part by binding DNA minor grooves in ETS binding sites and disrupting EWS-FLI1 binding at target promoters (<a href="#f3">Figure 3B</a>)<sup><a href="#ref-113">113</a>,<a href="#ref-130">130</a>,<a href="#ref-131">131</a></sup>. Very few studies (and only two phase II clinical trials) have investigated trabectedin in PCa, but the results were disappointing<sup><a href="#ref-132">132</a>,<a href="#ref-133">133</a></sup>. However, patients were not initially stratified by ERG status and the study did not use the newer drug lurbinectedin. These studies demonstrate that there are multiple ways to target ERG, directly or indirectly, and these therapies may be an effective option for patients with ETS<sup>+</sup> prostate tumors.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e2201>DNA repair mutations in prostate cancer</h2><p class="" id=d21098e2204>Despite having a low burden of point mutations compared with other cancers, PCa has a high rate of genomic instability (amplifications, deletions, and chromosomal rearrangements)<sup><a href="#ref-32">32</a></sup>. Genomic instability is a result of DNA damage, which can arise from many sources, including (but certainly not limited to) DNA replication stress, alkylating agents, mitotic chromosome segregation errors, and radiation<sup><a href="#ref-23">23</a>,<a href="#ref-134">134</a>,<a href="#ref-135">135</a></sup>. DNA can also be damaged as a result of transcriptional stress; AR has been reported to recruit topoisomerase enzymes to counter DNA torsional stress caused by transcription and enhancer looping<sup><a href="#ref-136">136</a>,<a href="#ref-137">137</a></sup>. An extreme form of genomic instability is chromothripsis, which occurs in about 20% to 30% of primary prostate tumors and involves acute chromosome shattering and reassembly, causing deletions and rearrangements<sup><a href="#ref-23">23</a>,<a href="#ref-138">138</a></sup>. Damage that breaks the phosphate backbone or requires repair via base excision repair, mismatch repair, or nucleotide excision repair will lead to single-strand breaks (SSBs)<sup><a href="#ref-134">134</a></sup>. If SSBs occur close together on opposite strands, double-strand breaks (DSBs) can occur, which are more severe and must be repaired by homologous recombination (HR) or non-homologous end joining (NHEJ) (<a href="#f4">Figure 4</a>). HR can occur only if a sister chromatid is present (late S or G<sub>2</sub> phase) and uses the non-damaged DNA as a template for error-free repair of the damaged chromatid, whereas NHEJ can repair DSBs at any cell cycle stage (predominantly G<sub>0</sub>/G<sub>1</sub>) but has the possibility of introducing deletions or insertions<sup><a href="#ref-139">139</a>,<a href="#ref-140">140</a></sup>. Further information on DNA damage-sensing and repair mechanisms can be found in several recent reviews<sup><a href="#ref-134">134</a>,<a href="#ref-141">141</a>,<a href="#ref-142">142</a></sup>.</p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure4.gif"><img alt="fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure4.gif"></a><div class=caption><h3>Figure 4. Simplified DNA repair pathway diagram.</h3><p id=d21098e2279>Single-strand breaks (SSBs) are recognized by a handful of proteins, including poly (ADP-ribose) polymerase (PARP) and RPA. PARP helps recruit DNA repair machinery to repair SSBs (blue shading). ATR is recruited to the site of damage and activates (phosphorylates) a variety of damage-sensing mediators, including CHK1, which in turn can activate p53 and, depending on other signals, pause the cell cycle until damage is repaired or induce apoptosis. Double-strand breaks (DSBs) recruit a variety of factors, including the M/R/N complex (MRE11, RAD50, and NBS1). This complex recruits and activates ATM, which phosphorylates DSB-sensing mediators, including CHK2. 53BP1 binds to M/R/N on loose DNA ends and promotes non-homologous end joining (NHEJ) repair (orange shading). During late S/G<sub>2</sub> phase, BRCA1 can be activated by ATM and compete with 53BP1 for binding at the M/R/N complex and aid resection of DNA ends to promote homologous recombination (HR) repair (green shading).</p></div></div><p class="" id=d21098e2289>Germline mutations in DNA repair genes are responsible for a variety of human hereditary diseases, many of which include a predisposition to cancer<sup><a href="#ref-143">143</a>,<a href="#ref-144">144</a></sup>. Two such genes are the key signaling kinases in the DNA damage response—ATM (primarily activated by DSB) and ATR (primarily activated by SSB)—which can activate other signaling proteins, including CHK1 (<i>CHEK1</i>) and CHK2 (<i>CHEK2</i>) (<a href="#f4">Figure 4</a>)<sup><a href="#ref-142">142</a></sup>. Two other important DNA repair genes are <i>BRCA1</i> and <i>BRCA2</i>, for which single-copy germline mutations increase the risk of multiple cancers, most significantly breast and ovarian cancer<sup><a href="#ref-145">145</a>–<a href="#ref-147">147</a></sup>. Mechanistically, BRCA1/BRCA2 are crucial for recruiting RAD51, which is required for HR. BRCA1 has multiple roles, including promoting loose-end resection and aiding RAD51 loading onto DNA<sup><a href="#ref-148">148</a></sup>. A recent study suggests that BRCA1 competes with 53BP1 for binding at DSBs and helps determine whether repair is shunted toward NHEJ or HR (<a href="#f4">Figure 4</a>)<sup><a href="#ref-149">149</a></sup>.</p><p class="" id=d21098e2337>In 2016, a multi-institutional study sequenced the germline DNA of nearly 700 men with mCRPC and observed that 11.8% of patients carried a germline mutation in a DNA repair gene, most frequently <i>BRCA2</i> (5.3%), <i>CHEK2</i> (1.9%), or <i>ATM</i> (1.6%) (<a href="#T3">Table 3</a>)<sup><a href="#ref-150">150</a></sup>. Furthermore, somatic metastatic tumor sequencing through the SU2C/PCF landscape project determined that about 20% of metastatic tumors have a DNA repair gene aberration<sup><a href="#ref-28">28</a></sup>. <i>BRCA2</i> germline mutations occur at about 0.3% in the general population and, though not enriched among all primary tumors, correlate with high-grade disease<sup><a href="#ref-22">22</a>,<a href="#ref-150">150</a>–<a href="#ref-152">152</a></sup>. For example, <i>BRCA2</i> tumors are more likely to show a pattern of intra-ductal carcinoma, which involves large tumor-filled prostate ducts with intact basal layers and correlates with poor prognosis<sup><a href="#ref-153">153</a>–<a href="#ref-155">155</a></sup>. This knowledge has led to an ongoing discussion about whether all men who present with metastatic PCa should be screened for BRCA status as well as those with localized disease where biopsies demonstrate intra-ductal carcinoma patterning<sup><a href="#ref-154">154</a>–<a href="#ref-156">156</a></sup>.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. DNA repair mutation rate in tumors and germline.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21098e2403 class=n-a></a><thead><a name=d21098e2405 class=n-a></a><tr><a name=d21098e2407 class=n-a></a><th align=left colspan=1 rowspan=2 valign=top><a name=d21098e2409 class=n-a></a>Gene</th><th align=left colspan=2 rowspan=1 valign=top><a name=d21098e2412 class=n-a></a>Tumor</th><th align=left colspan=3 rowspan=1 valign=top><a name=d21098e2415 class=n-a></a>Germline</th></tr><tr><a name=d21098e2419 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d21098e2421 class=n-a></a>Primary</th><th align=left colspan=1 rowspan=1><a name=d21098e2424 class=n-a></a>mCRPC</th><th align=left colspan=1 rowspan=1><a name=d21098e2427 class=n-a></a>Overall</th><th align=left colspan=1 rowspan=1><a name=d21098e2430 class=n-a></a>Primary</th><th align=left colspan=1 rowspan=1><a name=d21098e2433 class=n-a></a>mCRPC</th></tr></thead><tbody><a name=d21098e2438 class=n-a></a><tr><a name=d21098e2440 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e2442 class=n-a></a> <i>ATM</i> </td><td colspan=1 rowspan=1 style="background-color:#FF3B3B" valign=top><a name=d21098e2448 class=n-a></a> <b>6</b> </td><td colspan=1 rowspan=1 style="background-color:#FF3B3B" valign=top><a name=d21098e2454 class=n-a></a> <b>8</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2460 class=n-a></a> <b>0.3</b> </td><td colspan=1 rowspan=1 style="background-color:#2E74B5" valign=top><a name=d21098e2466 class=n-a></a> <b>1</b> </td><td colspan=1 rowspan=1 style="background-color:#2E74B5" valign=top><a name=d21098e2473 class=n-a></a> <b>1.6</b> </td></tr><tr><a name=d21098e2480 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e2482 class=n-a></a> <i>ATR</i> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2488 class=n-a></a> <b>0.3</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2494 class=n-a></a> <b>0.8</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2500 class=n-a></a> <b>0.1</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2506 class=n-a></a> <b>0</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2513 class=n-a></a> <b>0.3</b> </td></tr><tr><a name=d21098e2520 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e2522 class=n-a></a> <i>CHEK2</i> </td><td colspan=1 rowspan=1 style="background-color:#FFB3B3" valign=top><a name=d21098e2528 class=n-a></a> <b>3</b> </td><td colspan=1 rowspan=1 style="background-color:#FFB3B3" valign=top><a name=d21098e2534 class=n-a></a> <b>4</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2540 class=n-a></a> <b>0.6</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2546 class=n-a></a> <b>0.4</b> </td><td colspan=1 rowspan=1 style="background-color:#2E74B5" valign=top><a name=d21098e2553 class=n-a></a> <b>1.9</b> </td></tr><tr><a name=d21098e2560 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e2562 class=n-a></a> <i>BRCA1</i> </td><td colspan=1 rowspan=1 style="background-color:#2E74B5" valign=top><a name=d21098e2568 class=n-a></a> <b>1.2</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2574 class=n-a></a> <b>0.8</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2580 class=n-a></a> <b>0.2</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2586 class=n-a></a> <b>0.6</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2593 class=n-a></a> <b>0.9</b> </td></tr><tr><a name=d21098e2600 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d21098e2602 class=n-a></a> <i>BRCA2</i> </td><td colspan=1 rowspan=1 style="background-color:#FFB3B3" valign=top><a name=d21098e2608 class=n-a></a> <b>3</b> </td><td colspan=1 rowspan=1 style="background-color:#FF3B3B" valign=top><a name=d21098e2614 class=n-a></a> <b>11</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2620 class=n-a></a> <b>0.3</b> </td><td colspan=1 rowspan=1 style="background-color:#BDD6EE" valign=top><a name=d21098e2626 class=n-a></a> <b>0.2</b> </td><td colspan=1 rowspan=1 style="background-color:#FF3B3B" valign=top><a name=d21098e2633 class=n-a></a> <b>5.4</b> </td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21098e2644 class=n-a></a><p id=d21098e2646> Mutation frequencies (percentages) for selected DNA repair genes in primary tumors and metastatic castration-resistant prostate cancer (mCRPC) and in the germline of normal, primary, or mCRPC patients. Tumor mutation frequencies were calculated the same way as in <a href="#T1">Table 1</a> and <a href="#T2">Table 2</a>. Germline mutation frequencies include 692 mCRPC patients, 499 primary, and 53,105 overall (exome aggregation consortium)<sup><a href="#ref-150">150</a></sup>. Shading: light blue: 0–0.9%, dark blue: 1–2.9%, light red: 3–4.9%, dark red: ≥5%.</p></div></div></div><p class="" id=d21098e2662>Other studies have confirmed similar rates (about 8–12%) of germline DNA repair defects in patients with mCRPC but had conflicting results as to whether germline mutant patients respond better to anti-androgen therapy<sup><a href="#ref-157">157</a>–<a href="#ref-160">160</a></sup>. Providing evidence against better outcomes are reports that germline mutant patients did not respond any better to initial androgen deprivation<sup><a href="#ref-157">157</a></sup> and patients with mCRPC saw no additional benefit from abiraterone or enzalutamide<sup><a href="#ref-158">158</a></sup>. However, other studies observed that DNA repair-deficient mCRPC tumors responded better to abiraterone<sup><a href="#ref-160">160</a></sup> and mCRPC patients with germline <i>BRCA1/BRCA2/ATM</i> mutations showed a better rate of greater than 90% prostate-specific antigen (PSA) reduction (78% versus 28%) and overall survival at 4 years (~75% versus ~25%) on ARSi therapy<sup><a href="#ref-159">159</a></sup>. Although germline DNA repair mutations account for only about 12% of patients with mCRPC, it will be important to better understand how these patients will respond to anti-androgen therapies. Furthermore, the identification of DNA repair mutations (whether germline or somatic) may open a window to new therapeutic options for thousands of the roughly 30,000 men who succumb to metastatic disease every year in the US and also identify family members at increased risk for cancer<sup><a href="#ref-1">1</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e2699>Targeting poly(ADP-ribose) polymerase</h2><p class="" id=d21098e2702>For patients with tumors deficient in DSB repair, there is strong rationale for targeting poly(ADP-ribose) polymerase (PARP), a family of proteins that are required for sensing and repairing SSBs (<a href="#f4">Figure 4</a>)<sup><a href="#ref-161">161</a></sup>. Without PARP, SSBs will cause stalling of replication forks during DNA replication that leads to DSBs, which then require HR or NHEJ for repair. Thus, cells lacking <i>BRCA1</i> or <i>BRCA2</i> must rely on error-prone NHEJ for DSB repair and are highly sensitive to loss of PARP<sup><a href="#ref-161">161</a>–<a href="#ref-163">163</a></sup>. In 2014, the US Food and Drug Administration (FDA) approved olaparib, a PARP inhibitor (PARPi), for the treatment of BRCA-mutant ovarian cancer, where it was found to extend average progression-free survival from 4.3 to 11.2 months<sup><a href="#ref-164">164</a></sup>. Since then, two other PARPis have received FDA approval for BRCA-deficient ovarian cancer: rucaparib and niraparib. Currently, those and other PARPis are in various clinical trials and studies are investigating whether the combination of PARPis with DNA-crosslinking drugs (that is, platinum-based chemotherapeutics) will yield better patient outcomes<sup><a href="#ref-161">161</a>,<a href="#ref-165">165</a></sup>. Testing of PARPis in PCa patients with BRCA mutations is ongoing. The TOPARP trial (Trial of PARP Inhibition in Prostate Cancer) tested olaparib in men with mCRPC and reported exciting preliminary results demonstrating response rates of 88% (14/16) in those men with a DNA repair defect and 6% (2/33) in those men without, strongly supporting treatment stratification based on DNA repair deficiency<sup><a href="#ref-166">166</a></sup>. Currently, searches for “PARP inhibitor” in “prostate cancer” on ClinicalTrials.gov yield 13 clinical trials; only two of these trials are completed, and there are no public results yet<sup><a href="#ref-167">167</a>,<a href="#ref-168">168</a></sup>.</p><p class="" id=d21098e2748>Although most studies are ongoing, a 2018 report used retrospective analysis of an earlier study<sup><a href="#ref-150">150</a></sup> to examine whether PCa patients with germline DNA repair defects had different responses to ARSi, docetaxel, or PARPi<sup><a href="#ref-158">158</a></sup>. Of the previously treated patients, 60 out of 390 had germline mutations and 36% of those were treated with PARPi (some with platinum chemotherapeutic as well). Germline status had no statistically significant correlations with response to docetaxel, ARSi (abiraterone/enzalutamide), or PARPi<sup><a href="#ref-158">158</a></sup>. Being a retrospective analysis, this study comes with multiple caveats, including the lack of initial patient stratification, inconsistent treatment methods, and a relatively small number of patients with germline mutations who received PARPi treatment (total of 22, of which 16 were <i>BRCA2</i> mutant). In addition, the study did not have information about the tumor mutation landscape, so there could yet be a correlation between DNA repair mutations and PARPi response that was masked by confounding factors (for example, ETS fusion, <i>AR</i>, or <i>PTEN</i> status)<sup><a href="#ref-158">158</a></sup>. Ongoing trials may yet prove to be beneficial for patients with germline DNA repair defects, and further research is needed to better understand how these mutations affect response to androgen deprivation and other PCa therapy resistance.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e2780>SPOP mutation</h2><p class="" id=d21098e2783>One of the novel PCa alterations elucidated by genomic sequencing efforts is mutation of <i>SPOP</i><sup><a href="#ref-21">21</a></sup>. Heterozygous point mutations in <i>SPOP</i> occur in about 10% of primary and metastatic tumors (<a href="#T1">Table 1</a> and <a href="#T2">Table 2</a>) and are mutually exclusive to <i>PTEN</i> loss and ETS rearrangements. SPOP is an adapter component of the CUL3 E3-ligase complex, which has multiple degradation targets, including AR and its co-activators SRC-3 (<i>NCOA3</i>) and TRIM24 (<a href="#f5">Figure 5</a>)<sup><a href="#ref-169">169</a>–<a href="#ref-172">172</a></sup>. Other recently identified direct targets of SPOP are the BET family proteins: BRD2/3/4<sup><a href="#ref-173">173</a>–<a href="#ref-175">175</a></sup>. BET proteins are transcriptional co-activators that upregulate a variety of oncogenes, including <i>AR</i>, <i>MYC</i>, and <i>ERG</i><sup><a href="#ref-173">173</a></sup>. BET inhibitors are being investigated for use in PCa<sup><a href="#ref-181">181</a></sup>, but <i>SPOP</i> mutant tumors with elevated BET expression may be more resistant to such therapies<sup><a href="#ref-173">173</a>,<a href="#ref-181">181</a></sup>. Earlier this year, PD-L1 was also identified as an SPOP target, which has implications for immunotherapy and will be discussed later<sup><a href="#ref-179">179</a></sup>.</p><a name=f5 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure5.gif"><img alt="fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15784/fbf32d47-edc5-4cdf-9a14-3fba4949a9d2_figure5.gif"></a><div class=caption><h3>Figure 5. SPOP mutations and prostate cancer.</h3><p id=d21098e2866>SPOP adapts the CUL3 E3-ligase complex to directly target and degrade AR and the AR co-activators TRIM24, SRC-3, and BRD2/3/4<sup><a href="#ref-170">170</a>–<a href="#ref-176">176</a></sup>. Thus, loss of SPOP increases both AR and its cofactors, leading to increased AR signaling. (*) ERG has also been reported as a direct SPOP target, although this is a debated topic<sup><a href="#ref-176">176</a>–<a href="#ref-178">178</a></sup>. SPOP has been shown to target PD-L1, a key target of checkpoint inhibitor immunotherapies<sup><a href="#ref-179">179</a></sup>. For indirect mechanisms, <i>SPOP</i> mutation strongly correlates with deletion of <i>CHD1</i>, which leads to 53BP1 stabilization and preference for error-prone NHEJ DSB repair<sup><a href="#ref-58">58</a>,<a href="#ref-180">180</a></sup>. <i>SPOP</i> mutation also upregulates PI3K/mTOR signaling via an unknown mechanism, which aids tumor growth and survival<sup><a href="#ref-83">83</a></sup>. AR, androgen receptor; DSB, double-strand break; NHEJ, non-homologous end joining.</p></div></div><p class="" id=d21098e2912>ERG has also been reported as an SPOP target, although there are conflicting data in the literature for this relationship<sup><a href="#ref-176">176</a>–<a href="#ref-178">178</a></sup>. In support of the connection, two reports from 2015 identified ERG as a direct SPOP degradation target. One report found that knockdown of <i>SPOP</i> or <i>CUL3</i> in PC3 and DU145 cells increased ERG (but not ETV1 or ERF) protein expression by increasing protein half-life and that this could be blocked by inhibition of casein kinase I<sup><a href="#ref-177">177</a></sup>. The authors also used a tissue microarray with immunohistochemistry (IHC) (for ERG expression) and <i>in situ</i> hybridization (for <i>TMPRSS2-ERG</i> fusions) to identify 14 ERG-positive/fusion-negative primary tumors, of which five (36%) had <i>SPOP</i> mutations, suggesting that <i>SPOP</i> mutation may upregulate ERG without fusion events<sup><a href="#ref-177">177</a></sup>. The second study found that <i>SPOP</i> knockdown increased ERG in LNCaP, C4-2, PC3, and 22RV1 lines<sup><a href="#ref-176">176</a></sup>. Both studies reported that SPOP targets a recognition site coded by the fourth exon of <i>ERG</i> that is usually disrupted in <i>TMPRSS2-ERG</i> fusions (<a href="#f3">Figure 3</a>), thus suggesting that fusions not only cause transcriptional upregulation but also increase protein stability<sup><a href="#ref-176">176</a>,<a href="#ref-177">177</a></sup>.</p><p class="" id=d21098e2973>In 2017, a study using a GEM model of <i>SPOP</i> mutation (F133V) observed high-grade PIN at 6 months in <i>Pten<sup>−/+</sup></i> mice and prostate tumors in <i>Pten<sup>−/−</sup></i> mice by 12 months<sup><a href="#ref-82">82</a></sup>. Additionally, the authors found that <i>SPOP</i> mutation alone increases PI3K/mTOR signaling. Furthermore, while PI3K signaling has negative feedback on <i>AR</i>, <i>Pten<sup>−/−</sup>/SPOP<sup>F133V</sup></i> tumors maintain Ar and express high levels of its transcriptional targets (<i>Fkbp5</i>, <i>Psca</i>, and <i>Nkx3.1</i>)<sup><a href="#ref-82">82</a></sup>. Thus, SPOP appears to have key intersections between AR and PI3K pathways which may help explain its importance in PCa (<a href="#f5">Figure 5</a>). These findings, however, do not provide a reasonable explanation for the mutual exclusivity between <i>PTEN</i> loss and <i>SPOP</i> mutation in human PCa. In a 2018 report from the same group, the authors investigated potential effects on ERG with their GEM model. Unlike the investigators in the 2015 studies<sup><a href="#ref-176">176</a>,<a href="#ref-177">177</a></sup>, who observed that <i>SPOP</i> mutation or knockdown in PCa lines increased ERG protein, this group did not observe upregulated Erg or an Erg transcriptional signature in their <i>SPOP<sup>F133V</sup></i> mice<sup><a href="#ref-178">178</a></sup>. In addition, they detected ERG (by IHC) in only one out of 22 SPOP-mutant human tumor samples, leading them to conclude that mutant SPOP was not regulating ERG<sup><a href="#ref-178">178</a></sup>. One important lesson from these conflicting studies is that loss of SPOP protein does not appear to have the same functional consequence as overexpression of a mutant. Importantly, <i>SPOP</i> is rarely deleted in PCa tumors and the vast majority of mutations are in-frame missense point mutations. Clearly, additional research is needed to fully characterize SPOP mutants and understand how they differ in their interactions with wild-type SPOP targets.</p><p class="" id=d21098e3059><i>SPOP</i> has also been linked to DNA repair. <i>SPOP</i> mutant tumors have especially high rates of chromosomal rearrangements and share a transcriptional signature with <i>BRCA1</i> loss, implicating <i>SPOP</i> in genomic instability<sup><a href="#ref-182">182</a></sup>. Furthermore, one of the common associations with <i>SPOP</i> mutations is deletion of <i>CHD1</i>, which is involved in DSB repair and whose loss correlates with poor survival<sup><a href="#ref-24">24</a>,<a href="#ref-180">180</a>,<a href="#ref-183">183</a></sup>. A query on cBioPortal using all available PCa datasets shows that <i>CHD1</i> loss and <i>SPOP</i> mutation are significantly correlated (<i>p</i> &lt;0.01). Specifically, 57% of tumors with <i>CHD1</i> deletion (68/119) have an <i>SPOP</i> mutation and 29% of tumors with <i>SPOP</i> mutations (68/233) have <i>CHD1</i> deletion. A 2017 report demonstrated that <i>CHD1</i>-null cells (mouse stem cells and 22RV1) are more sensitive to olaparib (PARPi) and carboplatin and have increased 53BP1 protein stability, which promotes error-prone NHEJ repair (<a href="#f4">Figure 4</a>)<sup><a href="#ref-180">180</a></sup>. Furthermore, <i>PTEN</i> deletion is mutually exclusive to <i>CHD1</i> deletion, and PTEN-null tumors require <i>CHD1</i> for proliferation and survival<sup><a href="#ref-184">184</a></sup>. Thus, <i>CHD1</i> loss may partly explain why <i>SPOP</i> mutations are exclusive of <i>PTEN</i> loss. In summary, <i>SPOP</i> has been implicated in many key PCa pathways (AR, MYC, ERG, PI3K, and DNA repair) and work has only recently begun to uncover specific targets and oncogenic mechanisms. Better understanding of <i>SPOP</i>, including its connections with <i>ERG</i> and <i>CHD1</i>, will be needed to help choose successful targeting strategies.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e3166>Androgen receptor-negative prostate cancer</h2><p class="" id=d21098e3169>The vast majority of prostate tumors depend on the AR pathway for survival<sup><a href="#ref-28">28</a></sup>. However, there are small subsets of PCa whose frequency appears to be increasing, including neuroendocrine PCa (NEPC)<sup><a href="#ref-185">185</a></sup> and double-negative PCa (DNPC)<sup><a href="#ref-186">186</a></sup>, which lack AR expression and therefore are not sensitive to androgen deprivation or ARSi.</p><p class="" id=d21098e3184>Primary prostate tumors often show regions of neuroendocrine foci, but predominantly NEPC tumors (also referred to as ‘small cell’) are rare at initial diagnosis (&lt;2%)<sup><a href="#ref-5">5</a>,<a href="#ref-187">187</a>,<a href="#ref-188">188</a></sup>. However, since the advent of new ARSi therapies (abiraterone in 2011 and enzalutamide in 2012)<sup><a href="#ref-189">189</a>,<a href="#ref-190">190</a></sup>, there has been an increase in NEPC, which now accounts for about 15% of mCRPC and has become a mechanism of ARSi resistance<sup><a href="#ref-185">185</a>,<a href="#ref-186">186</a>,<a href="#ref-191">191</a></sup>. These tumors are typically more aggressive and are characterized by their lack of AR and expression of neuroendocrine-associated genes, such as chromogranin A (<i>CHGA</i>) and synaptophysin (<i>SYP</i>)<sup><a href="#ref-5">5</a>,<a href="#ref-185">185</a></sup>. NEPC tumors often show upregulation of stem-associated genes (for example, <i>SOX2</i> and <i>MYCN</i>)<sup><a href="#ref-192">192</a>–<a href="#ref-194">194</a></sup> and upregulation of genes associated with epithelial–mesenchymal transition (for example, <i>SNAI1</i> and <i>VIM</i>)<sup><a href="#ref-5">5</a></sup> and frequently lose expression of <i>TP53</i> and <i>RB1</i><sup><a href="#ref-195">195</a></sup>. Moreover, these molecular changes are also directly implicated in resistance to AR-targeting therapies<sup><a href="#ref-192">192</a>,<a href="#ref-195">195</a></sup>. Interestingly, NEPC tumors have <i>TMPRSS2-ERG</i> fusions at about the same rate as adenocarcinomas; however, owing to the lack of AR signaling, the expression levels of ERG are low in these tumors. These findings suggest that NEPC represents trans-differentiation from an androgen-responsive, epithelial-derived precursor, as opposed to the possibility that they originate from normal neuroendocrine cells, which make up less than 1% of cells in the normal prostate<sup><a href="#ref-38">38</a>,<a href="#ref-185">185</a></sup>.</p><p class="" id=d21098e3279>In addition to NEPC, there is a recently identified subtype called DNPC that lacks AR and NEPC markers<sup><a href="#ref-186">186</a>,<a href="#ref-196">196</a></sup>. For example, recent RNA sequencing and pathway analysis with mCRPC samples from 96 patients treated before or after 2012 (the advent of abiraterone/enzalutamide) identified an increase in patients with NEPC (6.3% to 13.3%) as well as an even larger increase in DNPC (5.4% to 23.3%)<sup><a href="#ref-186">186</a></sup>. It is also possible that DNPC is not an entirely distinct subset of PCa but rather an intermediate step on the way from adenocarcinoma to NEPC. An AR-negative LNCaP line (LNCaP<sup>APIPC</sup>), which lacks CHGA and SYP, was used to investigate the mechanisms driving DNPC. This line has diminished AKT signaling and relies on an upregulated autocrine FGF8 → FGFR → ERK signaling pathway for survival<sup><a href="#ref-186">186</a></sup>. Analysis of human tumor data and PDX lines with DNPC confirmed a pattern of upregulated FGFs (FGF1/8/9), FGFRs (FGFR1/2/3/4), and an ERK signature. Furthermore, LNCaP<sup>APIPC</sup> xenografts are sensitive to FGFR inhibitors (CH-5183284, PD173074)<sup><a href="#ref-186">186</a></sup>. Thus, targeting the FGFR/ERK signaling axis may be beneficial for patients with DNPC, although it has yet to be tested in clinical trials. Thus, while AR-negative PCa accounts for a minority of prostate tumors, they are becoming more common and will require a different therapeutic strategy than classic AR-positive PCa.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e3311>Immunotherapy</h2><p class="" id=d21098e3314>Recently, cancer immunotherapy has received significant attention and has demonstrated great potential across different types of cancer. Immunotherapies can broadly be grouped into three strategies: cancer vaccines, immune checkpoint inhibitors, and engineered live immune cell components. Cancer vaccines use tumor-specific proteins to generate a targeted immune response or tag tumors with a lethal, targetable protein. There are a handful of vaccine-based trials for PCa, although the only currently FDA-approved therapy is Sipuleucel-T (also known as Provenge<sup>®</sup>)<sup><a href="#ref-197">197</a></sup>. Sipuleucel-T uses prostatic acid phosphatase as a tumor antigen and has shown about 4- to 5-month extended survival for patients with mCRPC, while patients with lower baseline PSA level had even greater (about 13-month) survival<sup><a href="#ref-198">198</a>,<a href="#ref-199">199</a></sup>. Several additional PCa vaccines are being tested, and detailed information about those studies can be obtained in the cited reviews<sup><a href="#ref-197">197</a>,<a href="#ref-200">200</a></sup>.</p><p class="" id=d21098e3338>A second branch of immunotherapy is checkpoint inhibition, which attempts to re-activate cancer-targeting T cells that have been disarmed by tumors. The primary targets for checkpoint inhibition are CTLA-4, PD1, and the PD1 ligands PD-L1/PD-L2. An early checkpoint inhibitor is ipilimumab, which targets CTLA-4 and was approved by the FDA in 2011 for the treatment of melanoma. Ipilimumab has been tested in PCa trials with mixed results; it was able to delay progression but did not extend overall survival<sup><a href="#ref-197">197</a>,<a href="#ref-201">201</a></sup>. However, this study had a small subset of patients (two out of 400) who had a complete response (&gt;4 years)<sup><a href="#ref-202">202</a></sup>. Other checkpoint inhibitors (for example, nivolumab, pembrolizumab, and atezolizumab) target PD1 or PD-L1/L2<sup><a href="#ref-200">200</a></sup>. In general, tumors with high mutational burden generate more novel proteins (neoantigens) and respond more favorably to immunotherapy<sup><a href="#ref-203">203</a>,<a href="#ref-204">204</a></sup>. A small subset of mCRPC tumors have mismatch repair defects (5% rate of deletion/mutation of <i>MSH2</i> or <i>MSH6</i> or both)<sup><a href="#ref-27">27</a>–<a href="#ref-29">29</a></sup> and exhibit a hypermutated phenotype<sup><a href="#ref-205">205</a></sup>. Interestingly, mismatch repair defects appear to be enriched in the most aggressive primary tumors. In one study, 40% of samples with intra-ductal carcinoma (four out of 10) showed loss of <i>MSH2</i>, <i>MSH6</i>, or <i>MLH1</i><sup><a href="#ref-206">206</a></sup>. Another investigation analyzed 1,133 primary and NEPC tumors by IHC via tissue microarray and observed that 8% of Gleason pattern five tumors (seven out of 91) had loss of MSH2 protein (due to technical issues, MSH6 and MHL1 were not included)<sup><a href="#ref-207">207</a></sup>. In 2017, the FDA approved pembrolizumab for the treatment of solid metastatic tumors with mismatch repair-defects, providing a new option for some patients with mCRPC<sup><a href="#ref-208">208</a></sup>.</p><p class="" id=d21098e3402>A recent study suggests that even tumors with low PD-L1 may be targetable using combination therapy. CDK4 was reported to negatively regulate PD-L1 via SPOP, and CDK4/6 inhibitors can cause upregulation of PD-L1 in mouse tissue and breast cancer xenografts<sup><a href="#ref-179">179</a></sup>. The authors went on to show that 80% of SPOP-mutant tumors (12 out of 15) had high PD-L1 by IHC staining versus 10% of the non-mutant SPOP tumors. Thus, SPOP-mutant tumors are likely to express PD-L1 and benefit from checkpoint inhibitory therapy, while other tumors may be driven to express PD-L1 by CDK4/6 inhibition.</p><p class="" id=d21098e3409>Another recent report focused on targeting myeloid-derived suppressor cells (MDSCs), which can shield tumors from T cells<sup><a href="#ref-209">209</a></sup>. A GEM model with Pb-driven knockout of <i>Pten</i>, <i>Trp53</i>, and <i>Smad4</i> was developed, and combinations of checkpoint inhibitors (anti-CTLA4 and anti-PD1 antibodies) plus inhibitors against multiple tyrosine kinases (dasatinib and cabozantinib) and PI3K (dactolisib/BEZ235) were evaluated. The authors found that combination therapy (checkpoint + tyrosine kinase + PI3K inhibition) had a major effect on decreasing tumor burden. Furthermore, they went on to discover that a key mechanism of this therapy was decreased cytokine production and MDSC tumor infiltration caused by the inhibition of tyrosine kinases and PI3K, which in turn sensitized the tumors to the checkpoint inhibition<sup><a href="#ref-209">209</a></sup>.</p><p class="" id=d21098e3430>The third branch of immunotherapy uses engineered immune cells, including chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T involves isolating patient immune cells and genetically engineering them to express a chimeric protein fusing a tumor-recognizing antibody region with a T-cell activation domain<sup><a href="#ref-210">210</a></sup>. The engineered cells are then grafted back into the patient. CAR-T cells can directly recognize tumors and trigger activation. This therapy has been extremely successful for treating B-cell acute lymphoblastic leukemia and B-cell lymphoma<sup><a href="#ref-210">210</a>,<a href="#ref-211">211</a></sup>. Trials with CAR-T therapies for PCa are under way and primarily involve using PSMA and PSCA as targeting antigens<sup><a href="#ref-212">212</a>,<a href="#ref-213">213</a></sup>. The multiple immunotherapy strategies of cancer vaccines, checkpoint inhibitors, and CAR-T continue to improve. Meanwhile, patient stratification based on tumor mutational burden, PD1/PD-L expression, and tumor-enriched antigens such as PSMA and PSCA will help direct these therapies to the patients most likely to benefit.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e3454>Conclusions</h2><p class="" id=d21098e3457>Owing to large-scale sequencing efforts (<a href="#f1">Figure 1</a>), the PCa field now has a near-comprehensive view of the mutational landscape of human PCa. These studies revealed that ETS fusions are the most frequent mutation in primary tumors, occurring in a little over half of cases (<a href="#f3">Figure 3</a>). Likewise, the second most common alteration, <i>PTEN</i> loss, occurs in about a quarter of primary tumors. PCa shows great resilience in evading androgen deprivation therapy and finding ways to maintain the AR pathway, but there is a growing number of tumors that do not express AR and rely on alternate survival mechanisms<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d21098e3473>Perhaps the key takeaway is that human prostate tumors are driven by a combination of alterations in a handful of signaling pathways. Understanding the role of these pathways in tumor initiation, progression, and therapeutic resistance will be critical in the future. In order to functionally test the role and mechanisms of these signaling pathways, there is a need to continually improve existing cell culture and animal models. Recently developed GEM models and organoid culture conditions can provide great opportunities for studying disease initiation, metastasis, and testing therapies against patient-derived tumors. As has become clear with other cancers, there will almost certainly be no single effective therapy for PCa. While most tumors will likely still benefit from improved AR-targeting therapies, it will be important to recognize subsets of tumors that may benefit from targeting other supporting mutations.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21098e3479>Abbreviations</h2><p class="" id=d21098e3482>AR, androgen receptor; ARSi, androgen receptor signaling inhibitor; CAR-T, chimeric antigen receptor T-cell; CTC, circulating tumor cell; DNPC, double-negative prostate cancer; DSB, double-strand break; FDA, US Food and Drug Administration; GEM, genetically engineered mouse; HR, homologous recombination; IHC, immunohistochemistry; LPB, large probasin promoter; LSL, Lox-STOP-Lox; mCRPC, metastatic castration-resistant prostate cancer; MDSC, myeloid-derived suppressor cell; NEPC, neuroendocrine prostate cancer; NHEJ, non-homologous end joining; PARP, poly(ADP-ribose) polymerase; PARPi, poly(ADP-ribose) polymerase inhibitor; Pb, Probasin; PCa, prostate cancer; PDX, patient-derived xenograft; PIN, prostatic intra-epithelial neoplasia; SSB, single-strand break; TCGA, The Cancer Genome Atlas; WES, whole exome sequencing; WGS, whole genome sequencing.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d21098e1 class=n-a></a><h2 class=main-title id=d21753>Competing interests</h2><p class=metadata-entry><a name=d21098e148 class=n-a></a><p id=d21098e149> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d21098e1 class=n-a></a><h2 class=main-title id=d21755>Grant information</h2><p>This work was funded by the National Institutes of Health: P30CA015704, P50CA097186, and R01CA176844.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d21098e3489 class=n-a></a><h2 class=main-title id=d21098e3491>Acknowledgments</h2><p class="" id=d21098e3494>We would like to thank Payel Chatterjee for helpful discussion and notes on DNA damage repair pathways. We apologize to colleagues where space constraints precluded citing their work.</p></div><div class=back-section><a name=d21098e3498 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d22524>References</h2><div class="section ref-list"><a name=d21098e3498 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732444477"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3505 class=n-a></a>Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. <i>CA Cancer J Clin.</i> 2018; <b>68</b>(1): 7–30. <a target=xrefwindow id=d21098e3513 href="http://www.ncbi.nlm.nih.gov/pubmed/29313949">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3516 href="http://dx.doi.org/10.3322/caac.21442">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732444477">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d21098e3529 class=n-a></a>Wong MC, Goggins WB, Wang HH, <i> et al.</i>: Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. <i>Eur Urol.</i> 2016; <b>70</b>(5): 862–74. <a target=xrefwindow id=d21098e3540 href="http://www.ncbi.nlm.nih.gov/pubmed/27289567">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3543 href="http://dx.doi.org/10.1016/j.eururo.2016.05.043">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d21098e3552 class=n-a></a>Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. <i>J Urol.</i> 2002; <b>168</b>(1): 9–12. <a target=xrefwindow id=d21098e3560 href="http://www.ncbi.nlm.nih.gov/pubmed/12050481">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3563 href="http://dx.doi.org/10.1016/S0022-5347(05)64820-3">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d21098e3572 class=n-a></a>Coutinho I, Day TK, Tilley WD, <i> et al.</i>: Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. <i>Endocr Relat Cancer.</i> 2016; <b>23</b>(12): T179–T197. <a target=xrefwindow id=d21098e3583 href="http://www.ncbi.nlm.nih.gov/pubmed/27799360">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3586 href="http://dx.doi.org/10.1530/ERC-16-0422">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732716062"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3595 class=n-a></a>Davies AH, Beltran H, Zoubeidi A: Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nat Rev Urol.</i> 2018; <b>15</b>(5): 271–86. <a target=xrefwindow id=d21098e3603 href="http://www.ncbi.nlm.nih.gov/pubmed/29460922">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3606 href="http://dx.doi.org/10.1038/nrurol.2018.22">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732716062">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732605776"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3620 class=n-a></a>Sheahan AV, Ellis L: Epigenetic reprogramming: A key mechanism driving therapeutic resistance. <i>Urol Oncol.</i> 2018; pii: S1078-1439(17)30650-6. <a target=xrefwindow id=d21098e3625 href="http://www.ncbi.nlm.nih.gov/pubmed/29395951">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3628 href="http://dx.doi.org/10.1016/j.urolonc.2017.12.021">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732605776">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727062327"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3641 class=n-a></a>Kgatle MM, Kalla AA, Islam MM, <i> et al.</i>: Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. <i>Prostate Cancer.</i> 2016; <b>2016</b>: 5653862. <a target=xrefwindow id=d21098e3652 href="http://www.ncbi.nlm.nih.gov/pubmed/27891254">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3655 href="http://dx.doi.org/10.1155/2016/5653862">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3659 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5116340">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727062327">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d21098e3672 class=n-a></a>Labbé DP, Zadra G, Ebot EM, <i> et al.</i>: Role of diet in prostate cancer: the epigenetic link. <i>Oncogene.</i> 2015; <b>34</b>(36): 4683–91. <a target=xrefwindow id=d21098e3683 href="http://www.ncbi.nlm.nih.gov/pubmed/25531313">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3686 href="http://dx.doi.org/10.1038/onc.2014.422">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3690 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4476943">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732189383"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3699 class=n-a></a>Lindqvist LM, Tandoc K, Topisirovic I, <i> et al.</i>: Cross-talk between protein synthesis, energy metabolism and autophagy in cancer. <i>Curr Opin Genet Dev.</i> 2018; <b>48</b>: 104–11. <a target=xrefwindow id=d21098e3710 href="http://www.ncbi.nlm.nih.gov/pubmed/29179096">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3713 href="http://dx.doi.org/10.1016/j.gde.2017.11.003">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3717 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5869074">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732189383">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727756336"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3730 class=n-a></a>Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, <i> et al.</i>: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature.</i> 2017; <b>547</b>(7661): 109–13. <a target=xrefwindow id=d21098e3741 href="http://www.ncbi.nlm.nih.gov/pubmed/28658205">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3744 href="http://dx.doi.org/10.1038/nature22964">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3748 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5505479">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727756336">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732750886"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3761 class=n-a></a>Alford AV, Brito JM, Yadav KK, <i> et al.</i>: The Use of Biomarkers in Prostate Cancer Screening and Treatment. <i>Rev Urol.</i> 2017; <b>19</b>(4): 221–34. <a target=xrefwindow id=d21098e3772 href="http://www.ncbi.nlm.nih.gov/pubmed/29472826">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3775 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5811879">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732750886">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d21098e3789 class=n-a></a>Bonci D, Coppola V, Patrizii M, <i> et al.</i>: A microRNA code for prostate cancer metastasis. <i>Oncogene.</i> 2016; <b>35</b>(9): 1180–92. <a target=xrefwindow id=d21098e3800 href="http://www.ncbi.nlm.nih.gov/pubmed/26073083">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3803 href="http://dx.doi.org/10.1038/onc.2015.176">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3807 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4803473">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d21098e3816 class=n-a></a>Fabris L, Ceder Y, Chinnaiyan AM, <i> et al.</i>: The Potential of MicroRNAs as Prostate Cancer Biomarkers. <i>Eur Urol.</i> 2016; <b>70</b>(2): 312–22. <a target=xrefwindow id=d21098e3827 href="http://www.ncbi.nlm.nih.gov/pubmed/26806656">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3830 href="http://dx.doi.org/10.1016/j.eururo.2015.12.054">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3834 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927364">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d21098e3843 class=n-a></a>Ganguly SS, Li X, Miranti CK: The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. <i>Front Oncol.</i> 2014; <b>4</b>: 364. <a target=xrefwindow id=d21098e3851 href="http://www.ncbi.nlm.nih.gov/pubmed/25566502">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3854 href="http://dx.doi.org/10.3389/fonc.2014.00364">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3857 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4266028">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732062897"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3866 class=n-a></a>Sfanos KS, Yegnasubramanian S, Nelson WG, <i> et al.</i>: The inflammatory microenvironment and microbiome in prostate cancer development. <i>Nat Rev Urol.</i> 2018; <b>15</b>(1): 11–24. <a target=xrefwindow id=d21098e3877 href="http://www.ncbi.nlm.nih.gov/pubmed/29089606">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3880 href="http://dx.doi.org/10.1038/nrurol.2017.167">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732062897">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d21098e3893 class=n-a></a>McGinley KF, Tay KJ, Moul JW: Prostate cancer in men of African origin. <i>Nat Rev Urol.</i> 2016; <b>13</b>(2): 99–107. <a target=xrefwindow id=d21098e3901 href="http://www.ncbi.nlm.nih.gov/pubmed/26718455">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3904 href="http://dx.doi.org/10.1038/nrurol.2015.298">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d21098e3913 class=n-a></a>Rhodes DR, Barrette TR, Rubin MA, <i> et al.</i>: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. <i>Cancer Res.</i> 2002; <b>62</b>(15): 4427–33. <a target=xrefwindow id=d21098e3924 href="http://www.ncbi.nlm.nih.gov/pubmed/12154050">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d21098e3934 class=n-a></a>Taylor BS, Schultz N, Hieronymus H, <i> et al.</i>: Integrative genomic profiling of human prostate cancer. <i>Cancer Cell.</i> 2010; <b>18</b>(1): 11–22. <a target=xrefwindow id=d21098e3945 href="http://www.ncbi.nlm.nih.gov/pubmed/20579941">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3948 href="http://dx.doi.org/10.1016/j.ccr.2010.05.026">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3198787">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d21098e3961 class=n-a></a>Berger MF, Lawrence MS, Demichelis F, <i> et al.</i>: The genomic complexity of primary human prostate cancer. <i>Nature.</i> 2011; <b>470</b>(7333): 214–20. <a target=xrefwindow id=d21098e3972 href="http://www.ncbi.nlm.nih.gov/pubmed/21307934">PubMed Abstract </a> | <a target=xrefwindow id=d21098e3975 href="http://dx.doi.org/10.1038/nature09744">Publisher Full Text </a> | <a target=xrefwindow id=d21098e3979 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3075885">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718003621"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e3988 class=n-a></a>Baca SC, Prandi D, Lawrence MS, <i> et al.</i>: Punctuated evolution of prostate cancer genomes. <i>Cell.</i> 2013; <b>153</b>(3): 666–77. <a target=xrefwindow id=d21098e3999 href="http://www.ncbi.nlm.nih.gov/pubmed/23622249">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4002 href="http://dx.doi.org/10.1016/j.cell.2013.03.021">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4006 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3690918">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718003621">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d21098e4019 class=n-a></a>Barbieri CE, Baca SC, Lawrence MS, <i> et al.</i>: Exome sequencing identifies recurrent <i>SPOP</i>, <i>FOXA1</i> and <i>MED12</i> mutations in prostate cancer. <i>Nat Genet.</i> 2012; <b>44</b>(6): 685–9. <a target=xrefwindow id=d21098e4040 href="http://www.ncbi.nlm.nih.gov/pubmed/22610119">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4043 href="http://dx.doi.org/10.1038/ng.2279">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4046 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3673022">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d21098e4055 class=n-a></a>Cancer Genome Atlas Research Network: The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell.</i> 2015; <b>163</b>(4): 1011–25. <a target=xrefwindow id=d21098e4063 href="http://www.ncbi.nlm.nih.gov/pubmed/26544944">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4066 href="http://dx.doi.org/10.1016/j.cell.2015.10.025">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4069 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4695400">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727187920"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4078 class=n-a></a>Fraser M, Sabelnykova VY, Yamaguchi TN, <i> et al.</i>: Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature.</i> 2017; <b>541</b>(7637): 359–64. <a target=xrefwindow id=d21098e4089 href="http://www.ncbi.nlm.nih.gov/pubmed/28068672">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4092 href="http://dx.doi.org/10.1038/nature20788">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727187920">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733046555"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4106 class=n-a></a>Wedge DC, Gundem G, Mitchell T, <i> et al.</i>: Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nat Genet.</i> 2018; <b>50</b>(5): 682–92. <a target=xrefwindow id=d21098e4117 href="http://www.ncbi.nlm.nih.gov/pubmed/29662167">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4120 href="http://dx.doi.org/10.1038/s41588-018-0086-z">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733046555">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733073551"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4133 class=n-a></a>Espiritu SMG, Liu LY, Rubanova Y, <i> et al.</i>: The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell.</i> 2018; <b>173</b>(4): 1003–1013.e15. <a target=xrefwindow id=d21098e4144 href="http://www.ncbi.nlm.nih.gov/pubmed/29681457">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4147 href="http://dx.doi.org/10.1016/j.cell.2018.03.029">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733073551">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d21098e4160 class=n-a></a>Armenia J, Wankowicz SAM, Liu D, <i> et al.</i>: The long tail of oncogenic drivers in prostate cancer. <i>Nat Genet.</i> 2018; <b>50</b>(5): 645–51. <a target=xrefwindow id=d21098e4171 href="http://www.ncbi.nlm.nih.gov/pubmed/29610475">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4174 href="http://dx.doi.org/10.1038/s41588-018-0078-z">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718558344"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4183 class=n-a></a>Grasso CS, Wu Y, Robinson DR, <i> et al.</i>: The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature.</i> 2012; <b>487</b>(7406): 239–43. <a target=xrefwindow id=d21098e4194 href="http://www.ncbi.nlm.nih.gov/pubmed/22722839">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4197 href="http://dx.doi.org/10.1038/nature11125">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4201 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3396711">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718558344">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d21098e4214 class=n-a></a>Robinson D, Van Allen EM, Wu YM, <i> et al.</i>: Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell.</i> 2015; <b>162</b>(2): 454. <a target=xrefwindow id=d21098e4225 href="http://www.ncbi.nlm.nih.gov/pubmed/28843286">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4228 href="http://dx.doi.org/10.1016/j.cell.2015.06.053">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d21098e4237 class=n-a></a>Kumar A, Coleman I, Morrissey C, <i> et al.</i>: Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nat Med.</i> 2016; <b>22</b>(4): 369–78. <a target=xrefwindow id=d21098e4248 href="http://www.ncbi.nlm.nih.gov/pubmed/26928463">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4251 href="http://dx.doi.org/10.1038/nm.4053">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4255 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5045679">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d21098e4265 class=n-a></a>Beltran H, Prandi D, Mosquera JM, <i> et al.</i>: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nat Med.</i> 2016; <b>22</b>(3): 298–305. <a target=xrefwindow id=d21098e4276 href="http://www.ncbi.nlm.nih.gov/pubmed/26855148">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4279 href="http://dx.doi.org/10.1038/nm.4045">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4283 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4777652">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718228166"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4292 class=n-a></a>Lawrence MS, Stojanov P, Mermel CH, <i> et al.</i>: Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature.</i> 2014; <b>505</b>(7484): 495–501. <a target=xrefwindow id=d21098e4303 href="http://www.ncbi.nlm.nih.gov/pubmed/24390350">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4306 href="http://dx.doi.org/10.1038/nature12912">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4310 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4048962">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718228166">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d21098e4323 class=n-a></a>Barbieri CE, Rubin MA: Genomic rearrangements in prostate cancer. <i>Curr Opin Urol.</i> 2015; <b>25</b>(1): 71–6. <a target=xrefwindow id=d21098e4331 href="http://www.ncbi.nlm.nih.gov/pubmed/25393273">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4334 href="http://dx.doi.org/10.1097/MOU.0000000000000129">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4337 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4269103">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1119"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4346 class=n-a></a>Tomlins SA, Rhodes DR, Perner S, <i> et al.</i>: Recurrent fusion of <i>TMPRSS2</i> and ETS transcription factor genes in prostate cancer. <i>Science.</i> 2005; <b>310</b>(5748): 644–8. <a target=xrefwindow id=d21098e4360 href="http://www.ncbi.nlm.nih.gov/pubmed/16254181">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4364 href="http://dx.doi.org/10.1126/science.1117679">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1119">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d21098e4377 class=n-a></a>Cerami E, Gao J, Dogrusoz U, <i> et al.</i>: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. <i>Cancer Discov.</i> 2012; <b>2</b>(5): 401–4. <a target=xrefwindow id=d21098e4388 href="http://www.ncbi.nlm.nih.gov/pubmed/22588877">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4391 href="http://dx.doi.org/10.1158/2159-8290.CD-12-0095">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4395 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3956037">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d21098e4404 class=n-a></a>Gao J, Aksoy BA, Dogrusoz U, <i> et al.</i>: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <i>Sci Signal.</i> 2013; <b>6</b>(269): pl1. <a target=xrefwindow id=d21098e4415 href="http://www.ncbi.nlm.nih.gov/pubmed/23550210">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4418 href="http://dx.doi.org/10.1126/scisignal.2004088">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4422 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4160307">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727716859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4432 class=n-a></a>Bose R, Karthaus WR, Armenia J, <i> et al.</i>: ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. <i>Nature.</i> 2017; <b>546</b>(7660): 671–5. <a target=xrefwindow id=d21098e4443 href="http://www.ncbi.nlm.nih.gov/pubmed/28614298">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4446 href="http://dx.doi.org/10.1038/nature22820">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4450 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5576182">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727716859">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727623513"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4463 class=n-a></a>Huang FW, Mosquera JM, Garofalo A, <i> et al.</i>: Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function <i>ERF</i> Mutations. <i>Cancer Discov.</i> 2017; <b>7</b>(9): 973–83. <a target=xrefwindow id=d21098e4477 href="http://www.ncbi.nlm.nih.gov/pubmed/28515055">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4481 href="http://dx.doi.org/10.1158/2159-8290.CD-16-0960">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4484 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5836784">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727623513">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d21098e4497 class=n-a></a>Frank SB, Miranti CK: Disruption of prostate epithelial differentiation pathways and prostate cancer development. <i>Front Oncol.</i> 2013; <b>3</b>: 273. <a target=xrefwindow id=d21098e4505 href="http://www.ncbi.nlm.nih.gov/pubmed/24199173">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4508 href="http://dx.doi.org/10.3389/fonc.2013.00273">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4511 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3813973">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727713626"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4520 class=n-a></a>Mahajan K, Malla P, Lawrence HR, <i> et al.</i>: ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. <i>Cancer Cell.</i> 2017; <b>31</b>(6): 790–803.e8. <a target=xrefwindow id=d21098e4531 href="http://www.ncbi.nlm.nih.gov/pubmed/28609657">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4534 href="http://dx.doi.org/10.1016/j.ccell.2017.05.003">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4538 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5512571">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727713626">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d21098e4551 class=n-a></a>Miyamoto DT, Lee RJ, Stott SL, <i> et al.</i>: Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. <i>Cancer Discov.</i> 2012; <b>2</b>(11): 995–1003. <a target=xrefwindow id=d21098e4562 href="http://www.ncbi.nlm.nih.gov/pubmed/23093251">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4565 href="http://dx.doi.org/10.1158/2159-8290.CD-12-0222">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4569 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3508523">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d21098e4578 class=n-a></a>Miyamoto DT, Zheng Y, Wittner BS, <i> et al.</i>: RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. <i>Science.</i> 2015; <b>349</b>(6254): 1351–6. <a target=xrefwindow id=d21098e4589 href="http://www.ncbi.nlm.nih.gov/pubmed/26383955">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4592 href="http://dx.doi.org/10.1126/science.aab0917">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4596 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872391">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d21098e4606 class=n-a></a>Huang L, Ma F, Chapman A, <i> et al.</i>: Single-Cell Whole-Genome Amplification and Sequencing: Methodology and Applications. <i>Annu Rev Genomics Hum Genet.</i> 2015; <b>16</b>: 79–102. <a target=xrefwindow id=d21098e4617 href="http://www.ncbi.nlm.nih.gov/pubmed/26077818">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4620 href="http://dx.doi.org/10.1146/annurev-genom-090413-025352">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725415998"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4629 class=n-a></a>Gundem G, Van Loo P, Kremeyer B, <i> et al.</i>: The evolutionary history of lethal metastatic prostate cancer. <i>Nature.</i> 2015; <b>520</b>(7547): 353–7. <a target=xrefwindow id=d21098e4640 href="http://www.ncbi.nlm.nih.gov/pubmed/25830880">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4643 href="http://dx.doi.org/10.1038/nature14347">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4413032">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725415998">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d21098e4660 class=n-a></a>Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. <i>J Urol.</i> 2005; <b>173</b>(2): 342–59. <a target=xrefwindow id=d21098e4668 href="http://www.ncbi.nlm.nih.gov/pubmed/15643172">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4671 href="http://dx.doi.org/10.1097/01.ju.0000141580.30910.57">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728766261"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4680 class=n-a></a>Moad M, Hannezo E, Buczacki SJ, <i> et al.</i>: Multipotent Basal Stem Cells, Maintained in Localized Proximal Niches, Support Directed Long-Ranging Epithelial Flows in Human Prostates. <i>Cell Rep.</i> 2017; <b>20</b>(7): 1609–22. <a target=xrefwindow id=d21098e4691 href="http://www.ncbi.nlm.nih.gov/pubmed/28813673">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4694 href="http://dx.doi.org/10.1016/j.celrep.2017.07.061">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4698 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5565638">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728766261">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d21098e4711 class=n-a></a>Collins AT, Habib FK, Maitland NJ, <i> et al.</i>: Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. <i>J Cell Sci.</i> 2001; <b>114</b>(Pt 21): 3865–72. <a target=xrefwindow id=d21098e4722 href="http://www.ncbi.nlm.nih.gov/pubmed/11719553">PubMed Abstract </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d21098e4731 class=n-a></a>Litvinov IV, Vander Griend DJ, Xu Y, <i> et al.</i>: Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. <i>Cancer Res.</i> 2006; <b>66</b>(17): 8598–607. <a target=xrefwindow id=d21098e4742 href="http://www.ncbi.nlm.nih.gov/pubmed/16951173">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4745 href="http://dx.doi.org/10.1158/0008-5472.CAN-06-1228">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4124600">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d21098e4759 class=n-a></a>Lamb LE, Knudsen BS, Miranti CK: E-cadherin-mediated survival of androgen-receptor-expressing secretory prostate epithelial cells derived from a stratified <i>in vitro</i> differentiation model. <i>J Cell Sci.</i> 2010; <b>123</b>(Pt 2): 266–76. <a target=xrefwindow id=d21098e4770 href="http://www.ncbi.nlm.nih.gov/pubmed/20048343">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4773 href="http://dx.doi.org/10.1242/jcs.054502">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d21098e4782 class=n-a></a>Niranjan B, Lawrence MG, Papargiris MM, <i> et al.</i>: Primary culture and propagation of human prostate epithelial cells. <i>Methods Mol Biol.</i> 2013; <b>945</b>: 365–82. <a target=xrefwindow id=d21098e4793 href="http://www.ncbi.nlm.nih.gov/pubmed/23097118">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4796 href="http://dx.doi.org/10.1007/978-1-62703-125-7_22">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d21098e4805 class=n-a></a>Sroka IC, Anderson TA, McDaniel KM, <i> et al.</i>: The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion. <i>J Cell Physiol.</i> 2010; <b>224</b>(2): 283–8. <a target=xrefwindow id=d21098e4816 href="http://www.ncbi.nlm.nih.gov/pubmed/20432448">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4819 href="http://dx.doi.org/10.1002/jcp.22149">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4823 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4816210">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d21098e4832 class=n-a></a>Lamb LE, Zarif JC, Miranti CK: The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling. <i>Cancer Res.</i> 2011; <b>71</b>(7): 2739–49. <a target=xrefwindow id=d21098e4840 href="http://www.ncbi.nlm.nih.gov/pubmed/21310825">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4843 href="http://dx.doi.org/10.1158/0008-5472.CAN-10-2745">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d21098e4852 class=n-a></a>Drost J, Karthaus WR, Gao D, <i> et al.</i>: Organoid culture systems for prostate epithelial and cancer tissue. <i>Nat Protoc.</i> 2016; <b>11</b>(2): 347–58. <a target=xrefwindow id=d21098e4863 href="http://www.ncbi.nlm.nih.gov/pubmed/26797458">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4866 href="http://dx.doi.org/10.1038/nprot.2016.006">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4870 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4793718">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727643450"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e4879 class=n-a></a>Wang S, Gao D, Chen Y: The potential of organoids in urological cancer research. <i>Nat Rev Urol.</i> 2017; <b>14</b>(7): 401–14. <a target=xrefwindow id=d21098e4887 href="http://www.ncbi.nlm.nih.gov/pubmed/28534535">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4890 href="http://dx.doi.org/10.1038/nrurol.2017.65">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4893 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5558053">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727643450">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d21098e4907 class=n-a></a>Chu JH, Yu S, Hayward SW, <i> et al.</i>: Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer. <i>Prostate.</i> 2009; <b>69</b>(4): 428–42. <a target=xrefwindow id=d21098e4918 href="http://www.ncbi.nlm.nih.gov/pubmed/19107869">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4921 href="http://dx.doi.org/10.1002/pros.20897">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d21098e4930 class=n-a></a>Bello-DeOcampo D, Kleinman HK, Deocampo ND, <i> et al.</i>: Laminin-1 and alpha6beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. <i>Prostate.</i> 2001; <b>46</b>(2): 142–53. <a target=xrefwindow id=d21098e4941 href="http://www.ncbi.nlm.nih.gov/pubmed/11170142">PubMed Abstract </a> | <a target="xrefwindow" id="d21098e4944" href="http://dx.doi.org/10.1002/1097-0045(20010201)46:2<142::AID-PROS1018&gt;3.0.CO;2-B">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d21098e4953 class=n-a></a>Garraway IP, Sun W, Tran CP, <i> et al.</i>: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration <i>in vivo</i>. <i>Prostate.</i> 2010; <b>70</b>(5): 491–501. <a target=xrefwindow id=d21098e4967 href="http://www.ncbi.nlm.nih.gov/pubmed/19938015">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4971 href="http://dx.doi.org/10.1002/pros.21083">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2885946">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d21098e4983 class=n-a></a>Chen S, Principessa L, Isaacs JT: Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. <i>Prostate.</i> 2012; <b>72</b>(13): 1478–89. <a target=xrefwindow id=d21098e4991 href="http://www.ncbi.nlm.nih.gov/pubmed/22396312">PubMed Abstract </a> | <a target=xrefwindow id=d21098e4994 href="http://dx.doi.org/10.1002/pros.22503">Publisher Full Text </a> | <a target=xrefwindow id=d21098e4997 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3578386">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718765270"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5006 class=n-a></a>Gao D, Vela I, Sboner A, <i> et al.</i>: Organoid cultures derived from patients with advanced prostate cancer. <i>Cell.</i> 2014; <b>159</b>(1): 176–87. <a target=xrefwindow id=d21098e5017 href="http://www.ncbi.nlm.nih.gov/pubmed/25201530">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5020 href="http://dx.doi.org/10.1016/j.cell.2014.08.016">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5024 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4237931">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718765270">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d21098e5037 class=n-a></a>Wang M, Nagle RB, Knudsen BS, <i> et al.</i>: A basal cell defect promotes budding of prostatic intraepithelial neoplasia. <i>J Cell Sci.</i> 2017; <b>130</b>(1): 104–10. <a target=xrefwindow id=d21098e5048 href="http://www.ncbi.nlm.nih.gov/pubmed/27609833">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5051 href="http://dx.doi.org/10.1242/jcs.188177">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5394777">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d21098e5065 class=n-a></a>Stock K, Estrada MF, Vidic S, <i> et al.</i>: Capturing tumor complexity <i>in vitro</i>: Comparative analysis of 2D and 3D tumor models for drug discovery. <i>Sci Rep.</i> 2016; <b>6</b>: 28951. <a target=xrefwindow id=d21098e5079 href="http://www.ncbi.nlm.nih.gov/pubmed/27364600">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5083 href="http://dx.doi.org/10.1038/srep28951">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5086 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4929472">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d21098e5095 class=n-a></a>Sieh S, Taubenberger AV, Lehman ML, <i> et al.</i>: Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D <i>in vitro</i> culture reflect molecular changes during bone metastasis. <i>Bone.</i> 2014; <b>63</b>: 121–31. <a target=xrefwindow id=d21098e5109 href="http://www.ncbi.nlm.nih.gov/pubmed/24530694">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5113 href="http://dx.doi.org/10.1016/j.bone.2014.02.001">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d21098e5122 class=n-a></a>Wang R, Xu J, Juliette L, <i> et al.</i>: Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone. <i>Semin Cancer Biol.</i> 2005; <b>15</b>(5): 353–64. <a target=xrefwindow id=d21098e5133 href="http://www.ncbi.nlm.nih.gov/pubmed/15982899">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5136 href="http://dx.doi.org/10.1016/j.semcancer.2005.05.005">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d21098e5145 class=n-a></a>Nguyen HM, Vessella RL, Morrissey C, <i> et al.</i>: LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. <i>Prostate.</i> 2017; <b>77</b>(6): 654–71. <a target=xrefwindow id=d21098e5156 href="http://www.ncbi.nlm.nih.gov/pubmed/28156002">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5159 href="http://dx.doi.org/10.1002/pros.23313">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5163 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5354949">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d21098e5172 class=n-a></a>Park JW, Lee JK, Phillips JW, <i> et al.</i>: Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. <i>Proc Natl Acad Sci U S A.</i> 2016; <b>113</b>(16): 4482–7. <a target=xrefwindow id=d21098e5183 href="http://www.ncbi.nlm.nih.gov/pubmed/27044116">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5186 href="http://dx.doi.org/10.1073/pnas.1603645113">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5190 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4843433">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d21098e5199 class=n-a></a>Chua CW, Shibata M, Lei M, <i> et al.</i>: Single luminal epithelial progenitors can generate prostate organoids in culture. <i>Nat Cell Biol.</i> 2014; <b>16</b>(10): 951–61, 1–4. <a target=xrefwindow id=d21098e5210 href="http://www.ncbi.nlm.nih.gov/pubmed/25241035">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5213 href="http://dx.doi.org/10.1038/ncb3047">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5217 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4183706">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718765271"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5227 class=n-a></a>Karthaus WR, Iaquinta PJ, Drost J, <i> et al.</i>: Identification of multipotent luminal progenitor cells in human prostate organoid cultures. <i>Cell.</i> 2014; <b>159</b>(1): 163–75. <a target=xrefwindow id=d21098e5238 href="http://www.ncbi.nlm.nih.gov/pubmed/25201529">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5241 href="http://dx.doi.org/10.1016/j.cell.2014.08.017">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5245 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4772677">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718765271">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d21098e5258 class=n-a></a>Chambers KF, Mosaad EM, Russell PJ, <i> et al.</i>: Correction: 3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer. <i>PLoS One.</i> 2015; <b>10</b>(4): e0125641. <a target=xrefwindow id=d21098e5269 href="http://www.ncbi.nlm.nih.gov/pubmed/25901746">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5272 href="http://dx.doi.org/10.1371/journal.pone.0125641">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5276 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4406579">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d21098e5285 class=n-a></a>Edmondson R, Adcock AF, Yang L: Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins. <i>PLoS One.</i> 2016; <b>11</b>(16): e0158116. <a target=xrefwindow id=d21098e5293 href="http://www.ncbi.nlm.nih.gov/pubmed/27352049">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5296 href="http://dx.doi.org/10.1371/journal.pone.0158116">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4924873">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d21098e5308 class=n-a></a>Frese KK, Tuveson DA: Maximizing mouse cancer models. <i>Nat Rev Cancer.</i> 2007; <b>7</b>(9): 645–58. <a target=xrefwindow id=d21098e5316 href="http://www.ncbi.nlm.nih.gov/pubmed/17687385">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5319 href="http://dx.doi.org/10.1038/nrc2192">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1015774"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5328 class=n-a></a>Ellwood-Yen K, Graeber TG, Wongvipat J, <i> et al.</i>: Myc-driven murine prostate cancer shares molecular features with human prostate tumors. <i>Cancer Cell.</i> 2003; <b>4</b>(3): 223–38. <a target=xrefwindow id=d21098e5339 href="http://www.ncbi.nlm.nih.gov/pubmed/14522256">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5342 href="http://dx.doi.org/10.1016/S1535-6108(03)00197-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1015774">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d21098e5355 class=n-a></a>Klezovitch O, Risk M, Coleman I, <i> et al.</i>: A causal role for ERG in neoplastic transformation of prostate epithelium. <i>Proc Natl Acad Sci U S A.</i> 2008; <b>105</b>(6): 2105–10. <a target=xrefwindow id=d21098e5366 href="http://www.ncbi.nlm.nih.gov/pubmed/18245377">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5369 href="http://dx.doi.org/10.1073/pnas.0711711105">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5373 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2538886">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d21098e5383 class=n-a></a>Greenberg NM, DeMayo F, Finegold MJ, <i> et al.</i>: Prostate cancer in a transgenic mouse. <i>Proc Natl Acad Sci U S A.</i> 1995; <b>92</b>(8): 3439–43. <a target=xrefwindow id=d21098e5394 href="http://www.ncbi.nlm.nih.gov/pubmed/7724580">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5397 href="http://dx.doi.org/10.1073/pnas.92.8.3439 ">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5401 href="http://www.ncbi.nlm.nih.gov/pmc/articles/42182">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d21098e5410 class=n-a></a>Kasper S, Sheppard PC, Yan Y, <i> et al.</i>: Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. <i>Lab Invest.</i> 1998; <b>78</b>(3): 319–33. <a target=xrefwindow id=d21098e5421 href="http://www.ncbi.nlm.nih.gov/pubmed/9520945">PubMed Abstract </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1165162"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5430 class=n-a></a>Wang X, Kruithof-de Julio M, Economides KD, <i> et al.</i>: A luminal epithelial stem cell that is a cell of origin for prostate cancer. <i>Nature.</i> 2009; <b>461</b>(7263): 495–500. <a target=xrefwindow id=d21098e5441 href="http://www.ncbi.nlm.nih.gov/pubmed/19741607">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5444 href="http://dx.doi.org/10.1038/nature08361">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5448 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2800362">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1165162">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13398986"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5461 class=n-a></a>Van Keymeulen A, Rocha AS, Ousset M, <i> et al.</i>: Distinct stem cells contribute to mammary gland development and maintenance. <i>Nature.</i> 2011; <b>479</b>(7372): 189–93. <a target=xrefwindow id=d21098e5472 href="http://www.ncbi.nlm.nih.gov/pubmed/21983963">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5475 href="http://dx.doi.org/10.1038/nature10573">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13398986">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717963313"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5488 class=n-a></a>Ousset M, Van Keymeulen A, Bouvencourt G, <i> et al.</i>: Multipotent and unipotent progenitors contribute to prostate postnatal development. <i>Nat Cell Biol.</i> 2012; <b>14</b>(11): 1131–8. <a target=xrefwindow id=d21098e5499 href="http://www.ncbi.nlm.nih.gov/pubmed/23064263">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5502 href="http://dx.doi.org/10.1038/ncb2600">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717963313">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8507956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5515 class=n-a></a>Ding Z, Wu C, Chu GC, <i> et al.</i>: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature.</i> 2011; <b>470</b>(7333): 269–73. <a target=xrefwindow id=d21098e5526 href="http://www.ncbi.nlm.nih.gov/pubmed/21289624">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5529 href="http://dx.doi.org/10.1038/nature09677">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5533 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3753179">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8507956">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13967957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5547 class=n-a></a>Ding Z, Wu CJ, Jaskelioff M, <i> et al.</i>: Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. <i>Cell.</i> 2012; <b>148</b>(5): 896–907. <a target=xrefwindow id=d21098e5558 href="http://www.ncbi.nlm.nih.gov/pubmed/22341455">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5561 href="http://dx.doi.org/10.1016/j.cell.2012.01.039">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5565 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3629723">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13967957">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d21098e5578 class=n-a></a>Lesche R, Groszer M, Gao J, <i> et al.</i>: <i>Cre/loxP</i>-mediated inactivation of the murine <i>Pten</i> tumor suppressor gene. <i>Genesis.</i> 2002; <b>32</b>(2): 148–9. <a target=xrefwindow id=d21098e5596 href="http://www.ncbi.nlm.nih.gov/pubmed/11857804">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5599 href="http://dx.doi.org/10.1002/gene.10036">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d21098e5608 class=n-a></a>Zhou Z, Flesken-Nikitin A, Corney DC, <i> et al.</i>: Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. <i>Cancer Res.</i> 2006; <b>66</b>(16): 7889–98. <a target=xrefwindow id=d21098e5619 href="http://www.ncbi.nlm.nih.gov/pubmed/16912162">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5622 href="http://dx.doi.org/10.1158/0008-5472.CAN-06-0486">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718025020"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5631 class=n-a></a>Chen Y, Chi P, Rockowitz S, <i> et al.</i>: ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. <i>Nat Med.</i> 2013; <b>19</b>(8): 1023–9. <a target=xrefwindow id=d21098e5642 href="http://www.ncbi.nlm.nih.gov/pubmed/23817021">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5645 href="http://dx.doi.org/10.1038/nm.3216">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5649 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3737318">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718025020">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727407719"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5662 class=n-a></a>Blattner M, Liu D, Robinson BD, <i> et al.</i>: <i>SPOP</i> Mutation Drives Prostate Tumorigenesis <i>In Vivo</i> through Coordinate Regulation of PI3K/mTOR and AR Signaling. <i>Cancer Cell.</i> 2017; <b>31</b>(3): 436–51. <a target=xrefwindow id=d21098e5680 href="http://www.ncbi.nlm.nih.gov/pubmed/28292441 ">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5683 href="http://dx.doi.org/10.1016/j.ccell.2017.02.004">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5384998">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727407719">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d21098e5699 class=n-a></a>Kwon OJ, Zhang L, Wang J, <i> et al.</i>: Notch promotes tumor metastasis in a prostate-specific <i>Pten</i>-null mouse model. <i>J Clin Invest.</i> 2016; <b>126</b>(7): 2626–41. <a target=xrefwindow id=d21098e5713 href="http://www.ncbi.nlm.nih.gov/pubmed/27294523">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5717 href="http://dx.doi.org/10.1172/JCI84637">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4922719">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14262975"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e5730 class=n-a></a>Mulholland DJ, Kobayashi N, Ruscetti M, <i> et al.</i>: <i>Pten</i> loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. <i>Cancer Res.</i> 2012; <b>72</b>(7): 1878–89. <a target=xrefwindow id=d21098e5744 href="http://www.ncbi.nlm.nih.gov/pubmed/22350410">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5748 href="http://dx.doi.org/10.1158/0008-5472.CAN-11-3132">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5751 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3319847">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14262975">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d21098e5764 class=n-a></a>Wang J, Kobayashi T, Floc'h N, <i> et al.</i>: B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. <i>Cancer Res.</i> 2012; <b>72</b>(18): 4765–76. <a target=xrefwindow id=d21098e5775 href="http://www.ncbi.nlm.nih.gov/pubmed/22836754">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5778 href="http://dx.doi.org/10.1158/0008-5472.CAN-12-0820">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5782 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3445712">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d21098e5791 class=n-a></a>Baena E, Shao Z, Linn DE, <i> et al.</i>: ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. <i>Genes Dev.</i> 2013; <b>27</b>(6): 683–98. <a target=xrefwindow id=d21098e5802 href="http://www.ncbi.nlm.nih.gov/pubmed/23512661">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5805 href="http://dx.doi.org/10.1101/gad.211011.112">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3613614">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d21098e5818 class=n-a></a>Linn DE, Penney KL, Bronson RT, <i> et al.</i>: Deletion of Interstitial Genes between <i>TMPRSS2</i> and <i>ERG</i> Promotes Prostate Cancer Progression. <i>Cancer Res.</i> 2016; <b>76</b>(7): 1869–81. <a target=xrefwindow id=d21098e5836 href="http://www.ncbi.nlm.nih.gov/pubmed/26880803">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5839 href="http://dx.doi.org/10.1158/0008-5472.CAN-15-1911">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5842 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4873435">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d21098e5851 class=n-a></a>Yan Y, Sheppard PC, Kasper S, <i> et al.</i>: Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. <i>Prostate.</i> 1997; <b>32</b>(2): 129–39. <a target=xrefwindow id=d21098e5862 href="http://www.ncbi.nlm.nih.gov/pubmed/9215401">PubMed Abstract </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d21098e5871 class=n-a></a>Vasioukhin V, Degenstein L, Wise B, <i> et al.</i>: The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(15): 8551–6. <a target=xrefwindow id=d21098e5882 href="http://www.ncbi.nlm.nih.gov/pubmed/10411913">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5885 href="http://dx.doi.org/10.1073/pnas.96.15.8551 ">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5889 href="http://www.ncbi.nlm.nih.gov/pmc/articles/17554">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d21098e5899 class=n-a></a>Kwon OJ, Zhang L, Ittmann MM, <i> et al.</i>: Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(5): E592–600. <a target=xrefwindow id=d21098e5910 href="http://www.ncbi.nlm.nih.gov/pubmed/24367088">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5913 href="http://dx.doi.org/10.1073/pnas.1318157111">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5917 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3918789">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d21098e5926 class=n-a></a>Zhang X, Lee C, Ng PY, <i> et al.</i>: Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. <i>Prostate.</i> 2000; <b>43</b>(4): 278–85. <a target=xrefwindow id=d21098e5937 href="http://www.ncbi.nlm.nih.gov/pubmed/10861747">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5940 href="http://dx.doi.org/10.1002/1097-0045(20000601)43:4%3c278::AID-PROS7%3e3.0.CO;2-4">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d21098e5949 class=n-a></a>Di Cristofano A, Pesce B, Cordon-Cardo C, <i> et al.</i>: <i>Pten</i> is essential for embryonic development and tumour suppression. <i>Nat Genet.</i> 1998; <b>19</b>(4): 348–55. <a target=xrefwindow id=d21098e5963 href="http://www.ncbi.nlm.nih.gov/pubmed/9697695">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5967 href="http://dx.doi.org/10.1038/1235">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d21098e5976 class=n-a></a>Nguyen LT, Tretiakova MS, Silvis MR, <i> et al.</i>: ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. <i>Cancer Cell.</i> 2015; <b>27</b>(6): 797–808. <a target=xrefwindow id=d21098e5987 href="http://www.ncbi.nlm.nih.gov/pubmed/26058078">PubMed Abstract </a> | <a target=xrefwindow id=d21098e5990 href="http://dx.doi.org/10.1016/j.ccell.2015.05.005">Publisher Full Text </a> | <a target=xrefwindow id=d21098e5994 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4461839">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d21098e6003 class=n-a></a>Klezovitch O, Chevillet J, Mirosevich J, <i> et al.</i>: Hepsin promotes prostate cancer progression and metastasis. <i>Cancer Cell.</i> 2004; <b>6</b>(2): 185–95. <a target=xrefwindow id=d21098e6014 href="http://www.ncbi.nlm.nih.gov/pubmed/15324701">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6017 href="http://dx.doi.org/10.1016/j.ccr.2004.07.008">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d21098e6026 class=n-a></a>Abate-Shen C, Banach-Petrosky WA, Sun X, <i> et al.</i>: <i>Nkx3.1</i>; <i>Pten</i> mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. <i>Cancer Res.</i> 2003; <b>63</b>(14): 3886–90. <a target=xrefwindow id=d21098e6044 href="http://www.ncbi.nlm.nih.gov/pubmed/12873978">PubMed Abstract </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d21098e6054 class=n-a></a>Tang X, Mahajan SS, Nguyen LT, <i> et al.</i>: Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. <i>Oncotarget.</i> 2014; <b>5</b>(5): 1352–62. <a target=xrefwindow id=d21098e6065 href="http://www.ncbi.nlm.nih.gov/pubmed/24657880">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6068 href="http://dx.doi.org/10.18632/oncotarget.1817">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6072 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4012739">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d21098e6081 class=n-a></a>Valkenburg KC, Williams BO: Mouse models of prostate cancer. <i>Prostate Cancer.</i> 2011; <b>2011</b>: 895238. <a target=xrefwindow id=d21098e6089 href="http://www.ncbi.nlm.nih.gov/pubmed/22111002">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6092 href="http://dx.doi.org/10.1155/2011/895238">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3221286">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d21098e6104 class=n-a></a>Grabowska MM, DeGraff DJ, Yu X, <i> et al.</i>: Mouse models of prostate cancer: picking the best model for the question. <i>Cancer Metastasis Rev.</i> 2014; <b>33</b>(2–3): 377–97. <a target=xrefwindow id=d21098e6115 href="http://www.ncbi.nlm.nih.gov/pubmed/24452759">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6118 href="http://dx.doi.org/10.1007/s10555-013-9487-8">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6122 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4108581">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d21098e6131 class=n-a></a>Rea D, Del Vecchio V, Palma G, <i> et al.</i>: Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. <i>Biomed Res Int.</i> 2016; <b>2016</b>: 9750795. <a target=xrefwindow id=d21098e6142 href="http://www.ncbi.nlm.nih.gov/pubmed/27294148">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6145 href="http://dx.doi.org/10.1155/2016/9750795">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6149 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4887629">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d21098e6158 class=n-a></a>Wang Y, Revelo MP, Sudilovsky D, <i> et al.</i>: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. <i>Prostate.</i> 2005; <b>64</b>(2): 149–59. <a target=xrefwindow id=d21098e6169 href="http://www.ncbi.nlm.nih.gov/pubmed/15678503">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6172 href="http://dx.doi.org/10.1002/pros.20225">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d21098e6181 class=n-a></a>Corey E, Quinn JE, Bladou F, <i> et al.</i>: Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. <i>Prostate.</i> 2002; <b>52</b>(1): 20–33. <a target=xrefwindow id=d21098e6192 href="http://www.ncbi.nlm.nih.gov/pubmed/11992617">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6195 href="http://dx.doi.org/10.1002/pros.10091">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d21098e6205 class=n-a></a>Elkin M, Vlodavsky I: Tail vein assay of cancer metastasis. <i>Curr Protoc Cell Biol.</i> 2001; <b>Chapter 19</b>(1): Unit 19.2. <a target=xrefwindow id=d21098e6213 href="http://www.ncbi.nlm.nih.gov/pubmed/18228345">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6216 href="http://dx.doi.org/10.1002/0471143030.cb1902s12">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d21098e6225 class=n-a></a>Gao H, Korn JM, Ferretti S, <i> et al.</i>: High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. <i>Nat Med.</i> 2015; <b>21</b>(11): 1318–25. <a target=xrefwindow id=d21098e6236 href="http://www.ncbi.nlm.nih.gov/pubmed/26479923">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6239 href="http://dx.doi.org/10.1038/nm.3954">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d21098e6248 class=n-a></a>Toivanen R, Taylor RA, Pook DW, <i> et al.</i>: Breaking through a roadblock in prostate cancer research: an update on human model systems. <i>J Steroid Biochem Mol Biol.</i> 2012; <b>131</b>(3–5): 122–31. <a target=xrefwindow id=d21098e6259 href="http://www.ncbi.nlm.nih.gov/pubmed/22342674">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6262 href="http://dx.doi.org/10.1016/j.jsbmb.2012.01.005">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d21098e6271 class=n-a></a>Ellis WJ, Vessella RL, Buhler KR, <i> et al.</i>: Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. <i>Clin Cancer Res.</i> 1996; <b>2</b>(6): 1039–48. <a target=xrefwindow id=d21098e6282 href="http://www.ncbi.nlm.nih.gov/pubmed/9816265">PubMed Abstract </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d21098e6291 class=n-a></a>Mohamed AA, Tan SH, Mikhalkevich N, <i> et al.</i>: Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. <i>J Cancer.</i> 2010; <b>1</b>: 197–208. <a target=xrefwindow id=d21098e6302 href="http://www.ncbi.nlm.nih.gov/pubmed/21060730">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6305 href="http://dx.doi.org/10.7150/jca.1.197">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2974237">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d21098e6318 class=n-a></a>Liu H, Shi J, Wilkerson M, <i> et al.</i>: Immunohistochemical evaluation of ERG expression in various benign and malignant tissues. <i>Ann Clin Lab Sci.</i> 2013; <b>43</b>(1): 3–9. <a target=xrefwindow id=d21098e6329 href="http://www.ncbi.nlm.nih.gov/pubmed/23462600">PubMed Abstract </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d21098e6339 class=n-a></a>Hermans KG, van der Korput HA, <i> et al.</i>: Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. <i>Cancer Res.</i> 2008; <b>68</b>(18): 7541–9. <a target=xrefwindow id=d21098e6350 href="http://www.ncbi.nlm.nih.gov/pubmed/18794142">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6353 href="http://dx.doi.org/10.1158/0008-5472.CAN-07-5930">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1089486"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e6362 class=n-a></a>Tomlins SA, Laxman B, Dhanasekaran SM, <i> et al.</i>: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature.</i> 2007; <b>448</b>(7153): 595–9. <a target=xrefwindow id=d21098e6373 href="http://www.ncbi.nlm.nih.gov/pubmed/17671502">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6376 href="http://dx.doi.org/10.1038/nature06024">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1089486">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727443709"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e6389 class=n-a></a>Wang X, Qiao Y, Asangani IA, <i> et al.</i>: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell.</i> 2017; <b>31</b>(4): 532–548.e7. <a target=xrefwindow id=d21098e6400 href="http://www.ncbi.nlm.nih.gov/pubmed/%0928344039">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6403 href="http://dx.doi.org/10.1016/j.ccell.2017.02.017">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6407 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5443258">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727443709">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d21098e6420 class=n-a></a>Winters B, Brown L, Coleman I, <i> et al.</i>: Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279. <i>Anticancer Res.</i> 2017; <b>37</b>(7): 3385–96. <a target=xrefwindow id=d21098e6431 href="http://www.ncbi.nlm.nih.gov/pubmed/28668826">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6434 href="http://dx.doi.org/10.21873/anticanres.11705">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d21098e6443 class=n-a></a>Rahim S, Minas T, Hong SH, <i> et al.</i>: A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. <i>PLoS One.</i> 2014; <b>9</b>(12): e114260. <a target=xrefwindow id=d21098e6454 href="http://www.ncbi.nlm.nih.gov/pubmed/25479232">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6457 href="http://dx.doi.org/10.1371/journal.pone.0114260">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6461 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4257561">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d21098e6470 class=n-a></a>Harlow ML, Maloney N, Roland J, <i> et al.</i>: Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. <i>Cancer Res.</i> 2016; <b>76</b>(22): 6657–68. <a target=xrefwindow id=d21098e6481 href="http://www.ncbi.nlm.nih.gov/pubmed/27697767">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6484 href="http://dx.doi.org/10.1158/0008-5472.CAN-16-0568">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6488 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5567825">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d21098e6498 class=n-a></a>Carver BS, Tran J, Gopalan A, <i> et al.</i>: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. <i>Nat Genet.</i> 2009; <b>41</b>(5): 619–24. <a target=xrefwindow id=d21098e6509 href="http://www.ncbi.nlm.nih.gov/pubmed/19396168">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6512 href="http://dx.doi.org/10.1038/ng.370">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6516 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2835150">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3635956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e6525 class=n-a></a>Zong Y, Xin L, Goldstein AS, <i> et al.</i>: ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(30): 12465–70. <a target=xrefwindow id=d21098e6536 href="http://www.ncbi.nlm.nih.gov/pubmed/19592505">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6539 href="http://dx.doi.org/10.1073/pnas.0905931106">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2708977">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3635956">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d21098e6556 class=n-a></a>Yu J, Yu J, Mani RS, <i> et al.</i>: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. <i>Cancer Cell.</i> 2010; <b>17</b>(5): 443–54. <a target=xrefwindow id=d21098e6567 href="http://www.ncbi.nlm.nih.gov/pubmed/20478527">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6570 href="http://dx.doi.org/10.1016/j.ccr.2010.03.018">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2874722">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d21098e6583 class=n-a></a>Chng KR, Chang CW, Tan SK, <i> et al.</i>: A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. <i>EMBO J.</i> 2012; <b>31</b>(12): 2810–23. <a target=xrefwindow id=d21098e6594 href="http://www.ncbi.nlm.nih.gov/pubmed/22531786">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6597 href="http://dx.doi.org/10.1038/emboj.2012.112">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6601 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3380210">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d21098e6610 class=n-a></a>Sun C, Dobi A, Mohamed A, <i> et al.</i>: <i>TMPRSS2-ERG</i> fusion, a common genomic alteration in prostate cancer activates <i>C-MYC</i> and abrogates prostate epithelial differentiation. <i>Oncogene.</i> 2008; <b>27</b>(40): 5348–53. <a target=xrefwindow id=d21098e6628 href="http://www.ncbi.nlm.nih.gov/pubmed/18542058">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6631 href="http://dx.doi.org/10.1038/onc.2008.183">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727715529"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e6640 class=n-a></a>Mohamed AA, Tan SH, Xavier CP, <i> et al.</i>: Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells. <i>Mol Cancer Res.</i> 2017; <b>15</b>(10): 1308–17. <a target=xrefwindow id=d21098e6651 href="http://www.ncbi.nlm.nih.gov/pubmed/28607007">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6654 href="http://dx.doi.org/10.1158/1541-7786.MCR-17-0058">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5626592">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727715529">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d21098e6672 class=n-a></a>Berger PL, Frank SB, Schulz VV, <i> et al.</i>: Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis. <i>Cancer Res.</i> 2014; <b>74</b>(12): 3357–68. <a target=xrefwindow id=d21098e6683 href="http://www.ncbi.nlm.nih.gov/pubmed/24762396">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6686 href="http://dx.doi.org/10.1158/0008-5472.CAN-13-3076">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6690 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4066454">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d21098e6699 class=n-a></a>Frank SB, Berger PL, Ljungman M, <i> et al.</i>: Human prostate luminal cell differentiation requires NOTCH3 induction by p38-MAPK and MYC. <i>J Cell Sci.</i> 2017; <b>130</b>(11): 1952–64. <a target=xrefwindow id=d21098e6710 href="http://www.ncbi.nlm.nih.gov/pubmed/28446540">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6713 href="http://dx.doi.org/10.1242/jcs.197152">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d21098e6722 class=n-a></a>Sreenath TL, Macalindong SS, Mikhalkevich N, <i> et al.</i>: <i>ETS</i> Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. <i>Sci Rep.</i> 2017; <b>7</b>(1): 1109. <a target=xrefwindow id=d21098e6736 href="http://www.ncbi.nlm.nih.gov/pubmed/28439080">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6740 href="http://dx.doi.org/10.1038/s41598-017-01187-4">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6743 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5430720">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d21098e6752 class=n-a></a>Kim TD, Jin F, Shin S, <i> et al.</i>: Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. <i>J Clin Invest.</i> 2016; <b>126</b>(2): 706–20. <a target=xrefwindow id=d21098e6763 href="http://www.ncbi.nlm.nih.gov/pubmed/26731476">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6766 href="http://dx.doi.org/10.1172/JCI78132">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6770 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4731184">Free Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d21098e6779 class=n-a></a>Kim TD, Shin S, Janknecht R: ETS transcription factor ERG cooperates with histone demethylase KDM4A. <i>Oncol Rep.</i> 2016; <b>35</b>(6): 3679–88. <a target=xrefwindow id=d21098e6787 href="http://www.ncbi.nlm.nih.gov/pubmed/27109047">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6790 href="http://dx.doi.org/10.3892/or.2016.4747">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6793 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4869937">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727506696"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e6802 class=n-a></a>Liu CY, Yu T, Huang Y, <i> et al.</i>: ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer. <i>J Biol Chem.</i> 2017; <b>292</b>(22): 9420–30. <a target=xrefwindow id=d21098e6813 href="http://www.ncbi.nlm.nih.gov/pubmed/28408625">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6816 href="http://dx.doi.org/10.1074/jbc.M117.783787">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6820 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5454120">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727506696">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d21098e6834 class=n-a></a>Hagenbuchner J, Ausserlechner MJ: Targeting transcription factors by small compounds--Current strategies and future implications. <i>Biochem Pharmacol.</i> 2016; <b>107</b>: 1–13. <a target=xrefwindow id=d21098e6842 href="http://www.ncbi.nlm.nih.gov/pubmed/26686579">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6845 href="http://dx.doi.org/10.1016/j.bcp.2015.12.006">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d21098e6854 class=n-a></a>Delattre O, Zucman J, Melot T, <i> et al.</i>: The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. <i>N Engl J Med.</i> 1994; <b>331</b>(5): 294–9. <a target=xrefwindow id=d21098e6865 href="http://www.ncbi.nlm.nih.gov/pubmed/8022439">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6868 href="http://dx.doi.org/10.1056/NEJM199408043310503">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d21098e6877 class=n-a></a>Kovar H, Amatruda J, Brunet E, <i> et al.</i>: The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. <i>Oncotarget.</i> 2016; <b>7</b>(8): 8613–24. <a target=xrefwindow id=d21098e6888 href="http://www.ncbi.nlm.nih.gov/pubmed/26802024">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6891 href="http://dx.doi.org/10.18632/oncotarget.6937">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6895 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4890991">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d21098e6904 class=n-a></a>Feng FY, Brenner JC, Hussain M, Chinnaiyan AM: Molecular pathways: targeting ETS gene fusions in cancer. <i>Clin Cancer Res.</i> 2014; <b>20</b>(17): 4442–8. <a target=xrefwindow id=d21098e6912 href="http://www.ncbi.nlm.nih.gov/pubmed/24958807">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6915 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0275">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4155001">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d21098e6927 class=n-a></a>Leal JF, Martínez-Díez M, García-Hernández V, <i> et al.</i>: PM01183, a new DNA minor groove covalent binder with potent <i>in vitro</i> and <i>in vivo</i> anti-tumour activity. <i>Br J Pharmacol.</i> 2010; <b>161</b>(5): 1099–110. <a target=xrefwindow id=d21098e6945 href="http://www.ncbi.nlm.nih.gov/pubmed/20977459">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6948 href="http://dx.doi.org/10.1111/j.1476-5381.2010.00945.x">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6951 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2998690">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d21098e6960 class=n-a></a>Larsen AK, Galmarini CM, D'Incalci M: Unique features of trabectedin mechanism of action. <i>Cancer Chemother Pharmacol.</i> 2016; <b>77</b>(4): 663–71. <a target=xrefwindow id=d21098e6968 href="http://www.ncbi.nlm.nih.gov/pubmed/26666647">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6971 href="http://dx.doi.org/10.1007/s00280-015-2918-1">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d21098e6981 class=n-a></a>Acikgoz E, Guven U, Duzagac F, <i> et al.</i>: Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells. <i>PLoS One.</i> 2015; <b>10</b>(10): e0141090. <a target=xrefwindow id=d21098e6992 href="http://www.ncbi.nlm.nih.gov/pubmed/26485709">PubMed Abstract </a> | <a target=xrefwindow id=d21098e6995 href="http://dx.doi.org/10.1371/journal.pone.0141090">Publisher Full Text </a> | <a target=xrefwindow id=d21098e6999 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4618065">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d21098e7008 class=n-a></a>Michaelson MD, Bellmunt J, Hudes GR, <i> et al.</i>: Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. <i>Ann Oncol.</i> 2012; <b>23</b>(5): 1234–40. <a target=xrefwindow id=d21098e7019 href="http://www.ncbi.nlm.nih.gov/pubmed/21930687">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7022 href="http://dx.doi.org/10.1093/annonc/mdr399">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3945398">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d21098e7035 class=n-a></a>Sirbu BM, Cortez D: DNA damage response: three levels of DNA repair regulation. <i>Cold Spring Harb Perspect Biol.</i> 2013; <b>5</b>(8): a012724. <a target=xrefwindow id=d21098e7043 href="http://www.ncbi.nlm.nih.gov/pubmed/23813586">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7046 href="http://dx.doi.org/10.1101/cshperspect.a012724">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7049 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3721278">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d21098e7058 class=n-a></a>Mehta A, Haber JE: Sources of DNA double-strand breaks and models of recombinational DNA repair. <i>Cold Spring Harb Perspect Biol.</i> 2014; <b>6</b>(9): a016428. <a target=xrefwindow id=d21098e7066 href="http://www.ncbi.nlm.nih.gov/pubmed/25104768">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7069 href="http://dx.doi.org/10.1101/cshperspect.a016428">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7072 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4142968">Free Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d21098e7081 class=n-a></a>Haffner MC, de Marzo AM, Meeker AK, <i> et al.</i>: Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? <i>Clin Cancer Res.</i> 2011; <b>17</b>(12): 3858–64. <a target=xrefwindow id=d21098e7092 href="http://www.ncbi.nlm.nih.gov/pubmed/21385925">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7095 href="http://dx.doi.org/10.1158/1078-0432.CCR-10-2044">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7099 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3117909">Free Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d21098e7108 class=n-a></a>Puc J, Kozbial P, Li W, <i> et al.</i>: Ligand-dependent enhancer activation regulated by topoisomerase-I activity. <i>Cell.</i> 2015; <b>160</b>(3): 367–80. <a target=xrefwindow id=d21098e7119 href="http://www.ncbi.nlm.nih.gov/pubmed/25619691">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7122 href="http://dx.doi.org/10.1016/j.cell.2014.12.023">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7126 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4422651">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d21098e7136 class=n-a></a>Kovtun IV, Murphy SJ, Johnson SH, <i> et al.</i>: Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer. <i>Oncotarget.</i> 2015; <b>6</b>(30): 29087–96. <a target=xrefwindow id=d21098e7147 href="http://www.ncbi.nlm.nih.gov/pubmed/26337081">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7150 href="http://dx.doi.org/10.18632/oncotarget.4900">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7154 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4745713">Free Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d21098e7163 class=n-a></a>Waters CA, Strande NT, Pryor JM, <i> et al.</i>: The fidelity of the ligation step determines how ends are resolved during nonhomologous end joining. <i>Nat Commun.</i> 2014; <b>5</b>: 4286. <a target=xrefwindow id=d21098e7174 href="http://www.ncbi.nlm.nih.gov/pubmed/24989324">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7177 href="http://dx.doi.org/10.1038/ncomms5286">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7181 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4107315">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d21098e7190 class=n-a></a>Zaboikin M, Zaboikina T, Freter C, <i> et al.</i>: Non-Homologous End Joining and Homology Directed DNA Repair Frequency of Double-Stranded Breaks Introduced by Genome Editing Reagents. <i>PLoS One.</i> 2017; <b>12</b>(1): e0169931. <a target=xrefwindow id=d21098e7201 href="http://www.ncbi.nlm.nih.gov/pubmed/28095454">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7204 href="http://dx.doi.org/10.1371/journal.pone.0169931">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7208 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5241150">Free Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d21098e7217 class=n-a></a>Jeggo PA, Pearl LH, Carr AM: DNA repair, genome stability and cancer: a historical perspective. <i>Nat Rev Cancer.</i> 2016; <b>16</b>(1): 35–42. <a target=xrefwindow id=d21098e7225 href="http://www.ncbi.nlm.nih.gov/pubmed/26667849">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7228 href="http://dx.doi.org/10.1038/nrc.2015.4">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d21098e7237 class=n-a></a>Maréchal A, Zou L: DNA damage sensing by the ATM and ATR kinases. <i>Cold Spring Harb Perspect Biol.</i> 2013; <b>5</b>(9): pii: a012716. <a target=xrefwindow id=d21098e7245 href="http://www.ncbi.nlm.nih.gov/pubmed/24003211">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7248 href="http://dx.doi.org/10.1101/cshperspect.a012716">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7251 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3753707">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732579836"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7260 class=n-a></a>Nalepa G, Clapp DW: Fanconi anaemia and cancer: an intricate relationship. <i>Nat Rev Cancer.</i> 2018; <b>18</b>(3): 168–85. <a target=xrefwindow id=d21098e7268 href="http://www.ncbi.nlm.nih.gov/pubmed/29376519">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7271 href="http://dx.doi.org/10.1038/nrc.2017.116">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732579836">F1000 Recommendation</a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d21098e7285 class=n-a></a>Fassihi H, Sethi M, Fawcett H, <i> et al.</i>: Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. <i>Proc Natl Acad Sci U S A.</i> 2016; <b>113</b>(9): E1236–45. <a target=xrefwindow id=d21098e7296 href="http://www.ncbi.nlm.nih.gov/pubmed/26884178">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7299 href="http://dx.doi.org/10.1073/pnas.1519444113">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7303 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4780618">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d21098e7312 class=n-a></a>Bayraktar S, Arun B: BRCA mutation genetic testing implications in the United States. <i>Breast.</i> 2017; <b>31</b>: 224–32. <a target=xrefwindow id=d21098e7320 href="http://www.ncbi.nlm.nih.gov/pubmed/27931006">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7323 href="http://dx.doi.org/10.1016/j.breast.2016.11.021">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d21098e7332 class=n-a></a>Aparicio T, Baer R, Gautier J: DNA double-strand break repair pathway choice and cancer. <i>DNA Repair (Amst).</i> 2014; <b>19</b>: 169–75. <a target=xrefwindow id=d21098e7340 href="http://www.ncbi.nlm.nih.gov/pubmed/24746645">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7343 href="http://dx.doi.org/10.1016/j.dnarep.2014.03.014">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7346 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4051845">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732305499"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7355 class=n-a></a>Leão RRN, Price AJ, James Hamilton R: Germline <i>BRCA</i> mutation in male carriers-ripe for precision oncology? <i>Prostate Cancer Prostatic Dis.</i> 2018; <b>21</b>(1): 48–56. <a target=xrefwindow id=d21098e7366 href="http://www.ncbi.nlm.nih.gov/pubmed/29242595">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7369 href="http://dx.doi.org/10.1038/s41391-017-0018-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732305499">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d21098e7382 class=n-a></a>Prakash R, Zhang Y, Feng W, <i> et al.</i>: Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. <i>Cold Spring Harb Perspect Biol.</i> 2015; <b>7</b>(4): a016600. <a target=xrefwindow id=d21098e7393 href="http://www.ncbi.nlm.nih.gov/pubmed/25833843">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7396 href="http://dx.doi.org/10.1101/cshperspect.a016600">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7400 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4382744">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d21098e7409 class=n-a></a>Liu Y, Cussiol JR, Dibitetto D, <i> et al.</i>: TOPBP1<sup>Dpb11</sup> plays a conserved role in homologous recombination DNA repair through the coordinated recruitment of 53BP1<sup>Rad9</sup>. <i>J Cell Biol.</i> 2017; <b>216</b>(3): 623–39. <a target=xrefwindow id=d21098e7427 href="http://www.ncbi.nlm.nih.gov/pubmed/28228534">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7430 href="http://dx.doi.org/10.1083/jcb.201607031">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5350513">Free Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d21098e7443 class=n-a></a>Pritchard CC, Mateo J, Walsh MF, <i> et al.</i>: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>N Engl J Med.</i> 2016; <b>375</b>(5): 443–53. <a target=xrefwindow id=d21098e7454 href="http://www.ncbi.nlm.nih.gov/pubmed/27433846">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7457 href="http://dx.doi.org/10.1056/NEJMoa1603144">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7461 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4986616">Free Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d21098e7470 class=n-a></a>Gallagher DJ, Gaudet MM, Pal P, <i> et al.</i>: Germline <i>BRCA</i> mutations denote a clinicopathologic subset of prostate cancer. <i>Clin Cancer Res.</i> 2010; <b>16</b>(7): 2115–21. <a target=xrefwindow id=d21098e7484 href="http://www.ncbi.nlm.nih.gov/pubmed/20215531">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7488 href="http://dx.doi.org/10.1158/1078-0432.CCR-09-2871">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7491 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3713614">Free Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d21098e7500 class=n-a></a>Mitra A, Fisher C, Foster CS, <i> et al.</i>: Prostate cancer in male <i>BRCA1</i> and <i>BRCA2</i> mutation carriers has a more aggressive phenotype. <i>Br J Cancer.</i> 2008; <b>98</b>(2): 502–7. <a target=xrefwindow id=d21098e7518 href="http://www.ncbi.nlm.nih.gov/pubmed/18182994">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7521 href="http://dx.doi.org/10.1038/sj.bjc.6604132">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7524 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2361443">Free Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d21098e7533 class=n-a></a>Tsuzuki T: Intraductal carcinoma of the prostate: a comprehensive and updated review. <i>Int J Urol.</i> 2015; <b>22</b>(2): 140–5. <a target=xrefwindow id=d21098e7541 href="http://www.ncbi.nlm.nih.gov/pubmed/25358604">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7544 href="http://dx.doi.org/10.1111/iju.12657">Publisher Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732569033"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7553 class=n-a></a>Isaacsson Velho P, Silberstein JL, Markowski MC, <i> et al.</i>: Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. <i>Prostate.</i> 2018; <b>78</b>(5): 401–7. <a target=xrefwindow id=d21098e7564 href="http://www.ncbi.nlm.nih.gov/pubmed/29368341">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7567 href="http://dx.doi.org/10.1002/pros.23484">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732569033">F1000 Recommendation</a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d21098e7580 class=n-a></a>Taylor RA, Fraser M, Livingstone J, <i> et al.</i>: Germline <i>BRCA2</i> mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nat Commun.</i> 2017; <b>8</b>: 13671. <a target=xrefwindow id=d21098e7594 href="http://www.ncbi.nlm.nih.gov/pubmed/28067867">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7598 href="http://dx.doi.org/10.1038/ncomms13671">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7601 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5227331">Free Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d21098e7611 class=n-a></a>Mateo J, Boysen G, Barbieri CE, <i> et al.</i>: DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>Eur Urol.</i> 2017; <b>71</b>(3): 417–25. <a target=xrefwindow id=d21098e7622 href="http://www.ncbi.nlm.nih.gov/pubmed/27590317">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7625 href="http://dx.doi.org/10.1016/j.eururo.2016.08.037">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d21098e7634 class=n-a></a>Annala M, Struss WJ, Warner EW, <i> et al.</i>: Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>Eur Urol.</i> 2017; <b>72</b>(1): 34–42. <a target=xrefwindow id=d21098e7645 href="http://www.ncbi.nlm.nih.gov/pubmed/28259476">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7648 href="http://dx.doi.org/10.1016/j.eururo.2017.02.023">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d21098e7657 class=n-a></a>Mateo J, Cheng HH, Beltran H, <i> et al.</i>: Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>Eur Urol.</i> 2018; <b>73</b>(5): 687–93. <a target=xrefwindow id=d21098e7668 href="http://www.ncbi.nlm.nih.gov/pubmed/29429804">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7671 href="http://dx.doi.org/10.1016/j.eururo.2018.01.010">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732665501"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7680 class=n-a></a>Antonarakis ES, Lu C, Luber B, <i> et al.</i>: Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. <i>Eur Urol.</i> 2018; <b>74</b>(2): 218–225. <a target=xrefwindow id=d21098e7691 href="http://www.ncbi.nlm.nih.gov/pubmed/29439820">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7694 href="http://dx.doi.org/10.1016/j.eururo.2018.01.035">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7698 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6045965">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732665501">F1000 Recommendation</a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732331482"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7711 class=n-a></a>Hussain M, Daignault-Newton S, Twardowski PW, <i> et al.</i>: Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>J Clin Oncol.</i> 2018; <b>36</b>(10): 991–9. <a target=xrefwindow id=d21098e7722 href="http://www.ncbi.nlm.nih.gov/pubmed/29261439">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7725 href="http://dx.doi.org/10.1200/JCO.2017.75.7310">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732331482">F1000 Recommendation</a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d21098e7738 class=n-a></a>Ohmoto A, Yachida S: Current status of poly(ADP-ribose) polymerase inhibitors and future directions. <i>Onco Targets Ther.</i> 2017; <b>10</b>: 5195–208. <a target=xrefwindow id=d21098e7746 href="http://www.ncbi.nlm.nih.gov/pubmed/29138572">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7749 href="http://dx.doi.org/10.2147/OTT.S139336">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7752 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5667784">Free Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d21098e7762 class=n-a></a>Bryant HE, Schultz N, Thomas HD, <i> et al.</i>: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. <i>Nature.</i> 2005; <b>434</b>(7035): 913–7. <a target=xrefwindow id=d21098e7773 href="http://www.ncbi.nlm.nih.gov/pubmed/15829966">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7776 href="http://dx.doi.org/10.1038/nature03443">Publisher Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1025649"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7785 class=n-a></a>Farmer H, McCabe N, Lord CJ, <i> et al.</i>: Targeting the DNA repair defect in <i>BRCA</i> mutant cells as a therapeutic strategy. <i>Nature.</i> 2005; <b>434</b>(7035): 917–21. <a target=xrefwindow id=d21098e7799 href="http://www.ncbi.nlm.nih.gov/pubmed/15829967">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7803 href="http://dx.doi.org/10.1038/nature03445">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1025649">F1000 Recommendation</a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d21098e7816 class=n-a></a>Ledermann J, Harter P, Gourley C, <i> et al.</i>: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by <i>BRCA</i> status in a randomised phase 2 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(8): 852–61. <a target=xrefwindow id=d21098e7830 href="http://www.ncbi.nlm.nih.gov/pubmed/24882434">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7834 href="http://dx.doi.org/10.1016/S1470-2045(14)70228-1">Publisher Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d21098e7843 class=n-a></a>George A, Kaye S, Banerjee S: Delivering widespread <i>BRCA</i> testing and PARP inhibition to patients with ovarian cancer. <i>Nat Rev Clin Oncol.</i> 2017; <b>14</b>(5): 284–96. <a target=xrefwindow id=d21098e7854 href="http://www.ncbi.nlm.nih.gov/pubmed/27958297">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7857 href="http://dx.doi.org/10.1038/nrclinonc.2016.191">Publisher Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725885514"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7866 class=n-a></a>Mateo J, Carreira S, Sandhu S, <i> et al.</i>: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>N Engl J Med.</i> 2015; <b>373</b>(18): 1697–708. <a target=xrefwindow id=d21098e7877 href="http://www.ncbi.nlm.nih.gov/pubmed/26510020">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7880 href="http://dx.doi.org/10.1056/NEJMoa1506859">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7884 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5228595">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725885514">F1000 Recommendation</a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1161824"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e7897 class=n-a></a>Fong PC, Boss DS, Yap TA, <i> et al.</i>: Inhibition of poly(ADP-ribose) polymerase in tumors from <i>BRCA</i> mutation carriers. <i>N Engl J Med.</i> 2009; <b>361</b>(2): 123–34. <a target=xrefwindow id=d21098e7911 href="http://www.ncbi.nlm.nih.gov/pubmed/19553641">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7915 href="http://dx.doi.org/10.1056/NEJMoa0900212">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1161824">F1000 Recommendation</a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d21098e7929 class=n-a></a>Kaufman B, Shapira-Frommer R, Schmutzler RK, <i> et al.</i>: Olaparib monotherapy in patients with advanced cancer and a germline <i>BRCA1/2</i> mutation. <i>J Clin Oncol.</i> 2015; <b>33</b>(3): 244–50. <a target=xrefwindow id=d21098e7943 href="http://www.ncbi.nlm.nih.gov/pubmed/25366685">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7947 href="http://dx.doi.org/10.1200/JCO.2014.56.2728">Publisher Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d21098e7956 class=n-a></a>An J, Wang C, Deng Y, <i> et al.</i>: Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. <i>Cell Rep.</i> 2014; <b>6</b>(4): 657–69. <a target=xrefwindow id=d21098e7967 href="http://www.ncbi.nlm.nih.gov/pubmed/24508459">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7970 href="http://dx.doi.org/10.1016/j.celrep.2014.01.013">Publisher Full Text </a> | <a target=xrefwindow id=d21098e7974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4361392">Free Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d21098e7983 class=n-a></a>Li C, Ao J, Fu J, <i> et al.</i>: Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. <i>Oncogene.</i> 2011; <b>30</b>(42): 4350–64. <a target=xrefwindow id=d21098e7994 href="http://www.ncbi.nlm.nih.gov/pubmed/21577200">PubMed Abstract </a> | <a target=xrefwindow id=d21098e7997 href="http://dx.doi.org/10.1038/onc.2011.151">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3158261">Free Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d21098e8010 class=n-a></a>Geng C, He B, Xu L, <i> et al.</i>: Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(17): 6997–7002. <a target=xrefwindow id=d21098e8021 href="http://www.ncbi.nlm.nih.gov/pubmed/23559371">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8024 href="http://dx.doi.org/10.1073/pnas.1304502110">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3637757">Free Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a name=d21098e8037 class=n-a></a>Groner AC, Cato L, de Tribolet-Hardy J, <i> et al.</i>: TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. <i>Cancer Cell.</i> 2016; <b>29</b>(6): 846–58. <a target=xrefwindow id=d21098e8048 href="http://www.ncbi.nlm.nih.gov/pubmed/27238081">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8051 href="http://dx.doi.org/10.1016/j.ccell.2016.04.012">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5124371">Free Full Text </a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d21098e8064 class=n-a></a>Dai X, Gan W, Li X, <i> et al.</i>: Prostate cancer-associated <i>SPOP</i> mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nat Med.</i> 2017; <b>23</b>(9): 1063–71. <a target=xrefwindow id=d21098e8078 href="http://www.ncbi.nlm.nih.gov/pubmed/28805820">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8082 href="http://dx.doi.org/10.1038/nm.4378">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8085 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5625299">Free Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d21098e8095 class=n-a></a>Janouskova H, El Tekle G, Bellini E, <i> et al.</i>: Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nat Med.</i> 2017; <b>23</b>(9): 1046–54. <a target=xrefwindow id=d21098e8106 href="http://www.ncbi.nlm.nih.gov/pubmed/28805821">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8109 href="http://dx.doi.org/10.1038/nm.4372">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8113 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5592092">Free Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d21098e8122 class=n-a></a>Zhang P, Wang D, Zhao Y, <i> et al.</i>: Intrinsic BET inhibitor resistance in <i>SPOP</i>-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. <i>Nat Med.</i> 2017; <b>23</b>(9): 1055–62. <a target=xrefwindow id=d21098e8136 href="http://www.ncbi.nlm.nih.gov/pubmed/28805822">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8140 href="http://dx.doi.org/10.1038/nm.4379">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8143 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5653288">Free Full Text </a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a name=d21098e8152 class=n-a></a>An J, Ren S, Murphy SJ, <i> et al.</i>: Truncated ERG Oncoproteins from <i>TMPRSS2-ERG</i> Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. <i>Mol Cell.</i> 2015; <b>59</b>(6): 904–16. <a target=xrefwindow id=d21098e8166 href="http://www.ncbi.nlm.nih.gov/pubmed/26344096">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8170 href="http://dx.doi.org/10.1016/j.molcel.2015.07.025">Publisher Full Text </a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d21098e8179 class=n-a></a>Gan W, Dai X, Lunardi A, <i> et al.</i>: SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. <i>Mol Cell.</i> 2015; <b>59</b>(6): 917–30. <a target=xrefwindow id=d21098e8190 href="http://www.ncbi.nlm.nih.gov/pubmed/26344095">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8193 href="http://dx.doi.org/10.1016/j.molcel.2015.07.026">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8197 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4575912">Free Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732223889"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8206 class=n-a></a>Shoag J, Liu D, Blattner M, <i> et al.</i>: <i>SPOP</i> mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. <i>J Clin Invest.</i> 2018; <b>128</b>(1): 381–6. <a target=xrefwindow id=d21098e8220 href="http://www.ncbi.nlm.nih.gov/pubmed/29202479">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8224 href="http://dx.doi.org/10.1172/JCI96551">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5749531">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732223889">F1000 Recommendation</a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732141032"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8240 class=n-a></a>Zhang J, Bu X, Wang H, <i> et al.</i>: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. <i>Nature.</i> 2018; <b>553</b>(7686): 91–5. <a target=xrefwindow id=d21098e8251 href="http://www.ncbi.nlm.nih.gov/pubmed/29160310">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8254 href="http://dx.doi.org/10.1038/nature25015">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8258 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5754234">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732141032">F1000 Recommendation</a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d21098e8272 class=n-a></a>Shenoy TR, Boysen G, Wang MY, <i> et al.</i>: CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. <i>Ann Oncol.</i> 2017; <b>28</b>(7): 1495–507. <a target=xrefwindow id=d21098e8283 href="http://www.ncbi.nlm.nih.gov/pubmed/28383660">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8286 href="http://dx.doi.org/10.1093/annonc/mdx165">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8290 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5834074">Free Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a name=d21098e8299 class=n-a></a>Markowski MC, De Marzo AM, Antonarakis ES: BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opin Investig Drugs.</i> 2017; <b>26</b>(12): 1391–7. <a target=xrefwindow id=d21098e8307 href="http://www.ncbi.nlm.nih.gov/pubmed/29032717">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8310 href="http://dx.doi.org/10.1080/13543784.2017.1393518">Publisher Full Text </a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725792100"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8319 class=n-a></a>Boysen G, Barbieri CE, Prandi D, <i> et al.</i>: <i>SPOP</i> mutation leads to genomic instability in prostate cancer. <i>eLife.</i> 2015; <b>4</b>: pii: e09207. <a target=xrefwindow id=d21098e8333 href="http://www.ncbi.nlm.nih.gov/pubmed/26374986">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8337 href="http://dx.doi.org/10.7554/eLife.09207">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4621745">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725792100">F1000 Recommendation</a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d21098e8353 class=n-a></a>Kari V, Mansour WY, Raul SK, <i> et al.</i>: Loss of <i>CHD1</i> causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. <i>EMBO Rep.</i> 2016; <b>17</b>(11): 1609–23. <a target=xrefwindow id=d21098e8367 href="http://www.ncbi.nlm.nih.gov/pubmed/27596623">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8371 href="http://dx.doi.org/10.15252/embr.201642352">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8374 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5090703">Free Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727280274"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8383 class=n-a></a>Zhao D, Lu X, Wang G, <i> et al.</i>: Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. <i>Nature.</i> 2017; <b>542</b>(7642): 484–8. <a target=xrefwindow id=d21098e8394 href="http://www.ncbi.nlm.nih.gov/pubmed/28166537">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8397 href="http://dx.doi.org/10.1038/nature21357">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8401 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5448706">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727280274">F1000 Recommendation</a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d21098e8414 class=n-a></a>Beltran H, Rickman DS, Park K, <i> et al.</i>: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discov.</i> 2011; <b>1</b>(6): 487–95. <a target=xrefwindow id=d21098e8425 href="http://www.ncbi.nlm.nih.gov/pubmed/22389870">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8428 href="http://dx.doi.org/10.1158/2159-8290.CD-11-0130">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8432 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3290518">Free Full Text </a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731931892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8442 class=n-a></a>Bluemn EG, Coleman IM, Lucas JM, <i> et al.</i>: Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell.</i> 2017; <b>32</b>(4): 474–489.e6. <a target=xrefwindow id=d21098e8453 href="http://www.ncbi.nlm.nih.gov/pubmed/29017058">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8456 href="http://dx.doi.org/10.1016/j.ccell.2017.09.003">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8460 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5750052">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731931892">F1000 Recommendation</a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a name=d21098e8473 class=n-a></a>Abbas F, Civantos F, Benedetto P, <i> et al.</i>: Small cell carcinoma of the bladder and prostate. <i>Urology.</i> 1995; <b>46</b>(5): 617–30. <a target=xrefwindow id=d21098e8484 href="http://www.ncbi.nlm.nih.gov/pubmed/7495110">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8487 href="http://dx.doi.org/10.1016/S0090-4295(99)80290-8">Publisher Full Text </a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a name=d21098e8496 class=n-a></a>Grigore AD, Ben-Jacob E, Farach-Carson MC: Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? <i>Front Oncol.</i> 2015; <b>5</b>: 37. <a target=xrefwindow id=d21098e8504 href="http://www.ncbi.nlm.nih.gov/pubmed/25785244">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8507 href="http://dx.doi.org/10.3389/fonc.2015.00037">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4347593">Free Full Text </a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d21098e8519 class=n-a></a>Kluetz PG, Ning Y, Maher VE, <i> et al.</i>: Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. <i>Clin Cancer Res.</i> 2013; <b>19</b>(24): 6650–6. <a target=xrefwindow id=d21098e8530 href="http://www.ncbi.nlm.nih.gov/pubmed/24150234">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8533 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-2134">Publisher Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d21098e8542 class=n-a></a>Ning YM, Pierce W, Maher VE, <i> et al.</i>: Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary. <i>Clin Cancer Res.</i> 2013; <b>19</b>(22): 6067–73. <a target=xrefwindow id=d21098e8553 href="http://www.ncbi.nlm.nih.gov/pubmed/24141628">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8556 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-1763">Publisher Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a name=d21098e8565 class=n-a></a>Watson PA, Arora VK, Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. <i>Nat Rev Cancer.</i> 2015; <b>15</b>(12): 701–11. <a target=xrefwindow id=d21098e8573 href="http://www.ncbi.nlm.nih.gov/pubmed/26563462">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8576 href="http://dx.doi.org/10.1038/nrc4016">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8579 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4771416">Free Full Text </a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727173550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8589 class=n-a></a>Mu P, Zhang Z, Benelli M, <i> et al.</i>: <i>SOX2</i> promotes lineage plasticity and antiandrogen resistance in <i>TP53</i>- and <i>RB1</i>-deficient prostate cancer. <i>Science.</i> 2017; <b>355</b>(6320): 84–8. <a target=xrefwindow id=d21098e8610 href="http://www.ncbi.nlm.nih.gov/pubmed/28059768">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8613 href="http://dx.doi.org/10.1126/science.aah4307">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5247742">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727173550">F1000 Recommendation</a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a name=d21098e8629 class=n-a></a>Dardenne E, Beltran H, Benelli M, <i> et al.</i>: N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. <i>Cancer Cell.</i> 2016; <b>30</b>(4): 563–77. <a target=xrefwindow id=d21098e8640 href="http://www.ncbi.nlm.nih.gov/pubmed/27728805">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8643 href="http://dx.doi.org/10.1016/j.ccell.2016.09.005">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5540451">Free Full Text </a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a name=d21098e8656 class=n-a></a>Lee JK, Phillips JW, Smith BA, <i> et al.</i>: N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. <i>Cancer Cell.</i> 2016; <b>29</b>(4): 536–47. <a target=xrefwindow id=d21098e8667 href="http://www.ncbi.nlm.nih.gov/pubmed/27050099">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8670 href="http://dx.doi.org/10.1016/j.ccell.2016.03.001">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4829466">Free Full Text </a></span></li><li><a name=ref-195 class=n-a></a><span class=label>195. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727164983"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8683 class=n-a></a>Ku SY, Rosario S, Wang Y, <i> et al.</i>: <i>Rb1</i> and <i>Trp53</i> cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. <i>Science.</i> 2017; <b>355</b>(6320): 78–83. <a target=xrefwindow id=d21098e8701 href="http://www.ncbi.nlm.nih.gov/pubmed/28059767">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8704 href="http://dx.doi.org/10.1126/science.aah4199">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8707 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5367887">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727164983">F1000 Recommendation</a></span></li><li><a name=ref-196 class=n-a></a><span class=label>196. </span>&nbsp;<span class=citation><a name=d21098e8720 class=n-a></a>Wang W, Epstein JI: Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. <i>Am J Surg Pathol.</i> 2008; <b>32</b>(1): 65–71. <a target=xrefwindow id=d21098e8728 href="http://www.ncbi.nlm.nih.gov/pubmed/18162772">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8731 href="http://dx.doi.org/10.1097/PAS.0b013e318058a96b">Publisher Full Text </a></span></li><li><a name=ref-197 class=n-a></a><span class=label>197. </span>&nbsp;<span class=citation><a name=d21098e8740 class=n-a></a>Schepisi G, Farolfi A, Conteduca V, <i> et al.</i>: Immunotherapy for Prostate Cancer: Where We Are Headed. <i>Int J Mol Sci.</i> 2017; <b>18</b>(12): pii: E2627. <a target=xrefwindow id=d21098e8751 href="http://www.ncbi.nlm.nih.gov/pubmed/29206214">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8754 href="http://dx.doi.org/10.3390/ijms18122627">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8758 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5751230">Free Full Text </a></span></li><li><a name=ref-198 class=n-a></a><span class=label>198. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4568961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8768 class=n-a></a>Kantoff PW, Higano CS, Shore ND, <i> et al.</i>: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>N Engl J Med.</i> 2010; <b>363</b>(5): 411–22. <a target=xrefwindow id=d21098e8779 href="http://www.ncbi.nlm.nih.gov/pubmed/20818862">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8782 href="http://dx.doi.org/10.1056/NEJMoa1001294">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4568961">F1000 Recommendation</a></span></li><li><a name=ref-199 class=n-a></a><span class=label>199. </span>&nbsp;<span class=citation><a name=d21098e8795 class=n-a></a>Schellhammer PF, Chodak G, Whitmore JB, <i> et al.</i>: Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. <i>Urology.</i> 2013; <b>81</b>(6): 1297–302. <a target=xrefwindow id=d21098e8806 href="http://www.ncbi.nlm.nih.gov/pubmed/23582482">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8809 href="http://dx.doi.org/10.1016/j.urology.2013.01.061">Publisher Full Text </a></span></li><li><a name=ref-200 class=n-a></a><span class=label>200. </span>&nbsp;<span class=citation><a name=d21098e8818 class=n-a></a>Redman JM, Gulley JL, Madan RA: Combining immunotherapies for the treatment of prostate cancer. <i>Urol Oncol.</i> 2017; <b>35</b>(12): 694–700. <a target=xrefwindow id=d21098e8826 href="http://www.ncbi.nlm.nih.gov/pubmed/29146441">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8829 href="http://dx.doi.org/10.1016/j.urolonc.2017.09.024">Publisher Full Text </a></span></li><li><a name=ref-201 class=n-a></a><span class=label>201. </span>&nbsp;<span class=citation><a name=d21098e8838 class=n-a></a>Beer TM, Kwon ED, Drake CG, <i> et al.</i>: Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>J Clin Oncol.</i> 2017; <b>35</b>(1): 40–7. <a target=xrefwindow id=d21098e8849 href="http://www.ncbi.nlm.nih.gov/pubmed/28034081">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8852 href="http://dx.doi.org/10.1200/JCO.2016.69.1584">Publisher Full Text </a></span></li><li><a name=ref-202 class=n-a></a><span class=label>202. </span>&nbsp;<span class=citation><a name=d21098e8861 class=n-a></a>Cabel L, Loir E, Gravis G, <i> et al.</i>: Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. <i>J Immunother Cancer.</i> 2017; <b>5</b>: 31. <a target=xrefwindow id=d21098e8872 href="http://www.ncbi.nlm.nih.gov/pubmed/28428880">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8875 href="http://dx.doi.org/10.1186/s40425-017-0232-7">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8879 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5394619">Free Full Text </a></span></li><li><a name=ref-203 class=n-a></a><span class=label>203. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725528363"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e8888 class=n-a></a>Le DT, Uram JN, Wang H, <i> et al.</i>: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>N Engl J Med.</i> 2015; <b>372</b>(26): 2509–20. <a target=xrefwindow id=d21098e8899 href="http://www.ncbi.nlm.nih.gov/pubmed/26028255">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8902 href="http://dx.doi.org/10.1056/NEJMoa1500596">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8906 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4481136">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725528363">F1000 Recommendation</a></span></li><li><a name=ref-204 class=n-a></a><span class=label>204. </span>&nbsp;<span class=citation><a name=d21098e8920 class=n-a></a>Gubin MM, Artyomov MN, Mardis ER, <i> et al.</i>: Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>J Clin Invest.</i> 2015; <b>125</b>(9): 3413–21. <a target=xrefwindow id=d21098e8931 href="http://www.ncbi.nlm.nih.gov/pubmed/26258412">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8934 href="http://dx.doi.org/10.1172/JCI80008">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4588307">Free Full Text </a></span></li><li><a name=ref-205 class=n-a></a><span class=label>205. </span>&nbsp;<span class=citation><a name=d21098e8947 class=n-a></a>Pritchard CC, Morrissey C, Kumar A, <i> et al.</i>: Complex <i>MSH2</i> and <i>MSH6</i> mutations in hypermutated microsatellite unstable advanced prostate cancer. <i>Nat Commun.</i> 2014; <b>5</b>: 4988. <a target=xrefwindow id=d21098e8965 href="http://www.ncbi.nlm.nih.gov/pubmed/25255306">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8968 href="http://dx.doi.org/10.1038/ncomms5988">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4176888">Free Full Text </a></span></li><li><a name=ref-206 class=n-a></a><span class=label>206. </span>&nbsp;<span class=citation><a name=d21098e8980 class=n-a></a>Schweizer MT, Cheng HH, Tretiakova MS, <i> et al.</i>: Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget.</i> 2016; <b>7</b>(50): 82504–10. <a target=xrefwindow id=d21098e8991 href="http://www.ncbi.nlm.nih.gov/pubmed/27756888">PubMed Abstract </a> | <a target=xrefwindow id=d21098e8994 href="http://dx.doi.org/10.18632/oncotarget.12697">Publisher Full Text </a> | <a target=xrefwindow id=d21098e8998 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5347709">Free Full Text </a></span></li><li><a name=ref-207 class=n-a></a><span class=label>207. </span>&nbsp;<span class=citation><a name=d21098e9007 class=n-a></a>Guedes LB, Antonarakis ES, Schweizer MT, <i> et al.</i>: MSH2 Loss in Primary Prostate Cancer. <i>Clin Cancer Res.</i> 2017; <b>23</b>(22): 6863–74. <a target=xrefwindow id=d21098e9018 href="http://www.ncbi.nlm.nih.gov/pubmed/28790115">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9021 href="http://dx.doi.org/10.1158/1078-0432.CCR-17-0955">Publisher Full Text </a> | <a target=xrefwindow id=d21098e9025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5690834">Free Full Text </a></span></li><li><a name=ref-208 class=n-a></a><span class=label>208. </span>&nbsp;<span class=citation><a name=d21098e9034 class=n-a></a>Barroso-Sousa R, Ott PA: PD-1 inhibitors in endometrial cancer. <i>Oncotarget.</i> 2017; <b>8</b>(63): 106169–70. <a target=xrefwindow id=d21098e9042 href="http://www.ncbi.nlm.nih.gov/pubmed/29290936">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9045 href="http://dx.doi.org/10.18632/oncotarget.22583">Publisher Full Text </a> | <a target=xrefwindow id=d21098e9048 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5739721">Free Full Text </a></span></li><li><a name=ref-209 class=n-a></a><span class=label>209. </span>&nbsp;<span class=citation><a name=d21098e9057 class=n-a></a>Lu X, Horner JW, Paul E, <i> et al.</i>: Effective combinatorial immunotherapy for castration-resistant prostate cancer. <i>Nature.</i> 2017; <b>543</b>(7647): 728–32. <a target=xrefwindow id=d21098e9068 href="http://www.ncbi.nlm.nih.gov/pubmed/28321130">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9071 href="http://dx.doi.org/10.1038/nature21676">Publisher Full Text </a> | <a target=xrefwindow id=d21098e9075 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5374023">Free Full Text </a></span></li><li><a name=ref-210 class=n-a></a><span class=label>210. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730363594"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e9085 class=n-a></a>Brudno JN, Kochenderfer JN: Chimeric antigen receptor T-cell therapies for lymphoma. <i>Nat Rev Clin Oncol.</i> 2018; <b>15</b>(1): 31–46. <a target=xrefwindow id=d21098e9093 href="http://www.ncbi.nlm.nih.gov/pubmed/28857075">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9096 href="http://dx.doi.org/10.1038/nrclinonc.2017.128">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730363594">F1000 Recommendation</a></span></li><li><a name=ref-211 class=n-a></a><span class=label>211. </span>&nbsp;<span class=citation><a name=d21098e9109 class=n-a></a>Aldoss I, Bargou RC, Nagorsen D, <i> et al.</i>: Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. <i>Leukemia.</i> 2017; <b>31</b>(4): 777–87. <a target=xrefwindow id=d21098e9120 href="http://www.ncbi.nlm.nih.gov/pubmed/28028314">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9123 href="http://dx.doi.org/10.1038/leu.2016.391">Publisher Full Text </a></span></li><li><a name=ref-212 class=n-a></a><span class=label>212. </span>&nbsp;<span class=citation><a name=d21098e9132 class=n-a></a>Junghans RP, Ma Q, Rathore R, <i> et al.</i>: Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. <i>Prostate.</i> 2016; <b>76</b>(14): 1257–70. <a target=xrefwindow id=d21098e9143 href="http://www.ncbi.nlm.nih.gov/pubmed/27324746">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9146 href="http://dx.doi.org/10.1002/pros.23214">Publisher Full Text </a></span></li><li><a name=ref-213 class=n-a></a><span class=label>213. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732064938"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21098e9155 class=n-a></a>Priceman SJ, Gerdts EA, Tilakawardane D, <i> et al.</i>: Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncoimmunology.</i> 2018; <b>7</b>(2): e1380764. <a target=xrefwindow id=d21098e9166 href="http://www.ncbi.nlm.nih.gov/pubmed/29308300">PubMed Abstract </a> | <a target=xrefwindow id=d21098e9169 href="http://dx.doi.org/10.1080/2162402X.2017.1380764">Publisher Full Text </a> | <a target=xrefwindow id=d21098e9173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5749625">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732064938">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1173.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1173.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA<br/> <sup>2</sup> Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA<br/> <sup>3</sup> Departments of Medicine and Urology, University of Washington, Seattle, WA 98195, USA<br/> <sup>4</sup> Department of Pathology, University of Washington, Seattle, WA 98195, USA<br/> <p> <div class=margin-bottom> Sander Frank <br/> <span>Roles: </span> Conceptualization, Investigation, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Peter Nelson <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Valeri Vasioukhin <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1173/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 02 Aug 2018, 7:1173 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14499.1">https://doi.org/10.12688/f1000research.14499.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Frank S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15784 data-id=14499 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14499.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1173/v1/pdf?article_uuid=607f2be0-e00b-4aaa-b03c-9752bea6e453" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14499.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Frank S, Nelson P and Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1173 (<a href="https://doi.org/10.12688/f1000research.14499.1" target=_blank>https://doi.org/10.12688/f1000research.14499.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14499 id=mobile-track-article-signin-14499 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14499?target=/articles/7-1173.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15784 /> <input name=articleId type=hidden value=14499 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Emmanuel S Antonarakis</strong>, Department of Oncology, Johns Hopkins University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Christopher E Barbieri</strong>, The Caryl and Israel Englander Institute for Precision Medicine of Weill Cornell Medicine, and New York-Presbyterian Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 02 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1173.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1173.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37062-36419></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37064-36418></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1173/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>02 Aug 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Emmanuel S Antonarakis</strong>, Department of Oncology, Johns Hopkins University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Christopher E Barbieri</strong>, The Caryl and Israel Englander Institute for Precision Medicine of Weill Cornell Medicine, and New York-Presbyterian Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1173.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1173/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in prostate cancer research:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1173/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1173/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1173/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Frank S et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1173/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1173",
            templates : {
                twitter : "Recent advances in prostate cancer research: large-scale genomic.... Frank S et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1173/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14499/15784")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15784");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "36418": 0,
                           "36419": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "7767a73f-a2d7-4c73-acc1-6950a3ba0451";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1173.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1173.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1173.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1173.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1173.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>